



Published in final edited form as:

Cell Rep. 2021 March 16; 34(11): 108864. doi:10.1016/j.celrep.2021.108864.

Excision of mutagenic replication-blocking lesions suppresses cancer but promotes cytotoxicity and lethality in nitrosamine-exposed mice

Jennifer E. Kay^{1,2}, Joshua J. Corrigan^{1,2}, Amanda L. Armijo^{1,2,3}, Ilana S. Nazari¹, Ishwar N. Kohale^{1,2,4,5}, Dorothea K. Torous⁶, Svetlana L. Avlasevich⁶, Robert G. Croy^{1,2}, Dushan N. Wadduwage^{7,8}, Sebastian E. Carrasco³, Stephen D. Dertinger⁶, Forest M. White^{1,2,4,5}, John M. Essigmann^{1,2,9}, Leona D. Samson^{1,2,10}, Bevin P. Engelward^{1,2,*}

¹Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 01239, USA

²Center for Environmental Health Sciences Massachusetts Institute of Technology, Cambridge, MA 01239, USA

³Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA 01239, USA

⁴David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 01239, USA

⁵Center for Precision Cancer Medicine, Massachusetts Institute of Technology, Cambridge, MA 01239, USA

⁶Litron Laboratories, Rochester, NY 14623, USA

⁷The John Harvard Distinguished Science Fellows Program, Harvard University, Cambridge, MA 02138, USA

⁸Center for Advanced Imaging, Harvard University, Cambridge, MA 02138, USA

⁹Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 01239, USA

¹⁰Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 01239, USA

Summary

N-nitrosodimethylamine (NDMA) is a DNA methylating agent that has been discovered to contaminate water, food and drugs. The alkyladenine glycosylase (AAG) removes methylated bases to initiate the base excision repair (BER) pathway. To understand how gene-environment interactions impact disease susceptibility, we study *Aag*^{-/-} and *Aag*-overexpressing mice that harbor increased levels of either replication-blocking lesions (3-methyladenine, or 3MeA) or strand breaks (BER intermediates), respectively. Remarkably, the disease outcome switches from


*Lead contact: bevin@mit.edu; Tel: +1 617 258 0260; Fax: +1 617 258 0499.

Declaration of interests

SLA, DKT and SDD are employees of Litron Laboratories. Litron plans to sell kits for scoring micronucleated mouse hepatocytes via flow cytometry as described herein (In Vivo MicroFlow® PLUS ML Kits).

cancer to lethality simply by changing AAG levels. To understand the underlying basis for this observation, we integrate a suite of molecular, cellular and physiological analyses. We find that unrepaired 3MeA is somewhat toxic but highly mutagenic (promoting cancer), whereas excess strand breaks are poorly mutagenic and highly toxic (suppressing cancer and promoting lethality). We demonstrate that the levels of a single DNA repair protein tips the balance between blocks and breaks, and thus dictates the disease consequences of DNA damage.

Graphical Abstract



Keywords

alkyladenine glycosylase; DNA damage; replication blocking lesion; DNA strand break; nitrosamine; cancer; mutation; liver

INTRODUCTION

DNA damaging agents lead to changes in DNA structure that can promote cancer and other diseases. Distinct types of DNA modifications can result in very different biological consequences. Two major classes of DNA damage are blocking lesions (that inhibit DNA replication) and single strand breaks (SSBs). A challenge in understanding consequences of blocks versus breaks has been that most exposures induce a complex milieu of DNA lesions. To overcome this barrier, we manipulated the initial step in base excision repair (BER) to favor either excess blocking lesions or excess SSBs. Specifically, the mammalian alkyladenine DNA glycosylase (AAG; also known as MPG or ANPG) initiates BER by removing the damaged base to create an abasic site, which is then cleaved by AP endonuclease (APE1). In the dominant pathway, polymerase β removes the resultant 5' deoxyribose phosphate and inserts a single nucleotide, and the backbone is then sealed by ligation. As such, BER creates SSBs as requisite intermediates. For reviews of BER, see (Robertson et al., 2009), (Krokan and Bjoras, 2013), and (Wallace et al., 2012). By knocking

out *Aag*, it is possible to study the consequences of unrepaired 3-methyladenine (3MeA), a replication-blocking lesion. Conversely, by overexpressing *Aag*, the impact of elevated levels of downstream BER-intermediate SSBs can be evaluated. In this study, we find that there is a concert of responses that differ substantially between *Aag*-knockout mice (*Aag*^{-/-}, (Engelward et al., 1997)) and mice containing a transgenic construct for *Aag* overexpression (*AagTg*, (Meira et al., 2009), which have ~6x higher AAG activity in the liver compared to WT (Calvo et al., 2013)). Within days after a methylating exposure, distinct patterns of early physiological changes occur in the *Aag*^{-/-} and *AagTg* mice that correlate with either cancer (for *Aag*^{-/-}) or toxicity (for *AagTg*). The results from these studies thus provide a deeper mechanistic understanding of the biological consequences of blocks versus breaks, while also pointing to composite biomarkers that can potentially be used to predict the effects of seemingly small DNA structural changes that can have large biological consequences. Importantly, results show that by simply varying the level of a single DNA repair protein, which in turn tips the balance between blocks and breaks, an exposure can have radically different disease outcomes: cancer versus death.

It is well established that AAG modulates responses of cells and animals to DNA methylating agents (Ensminger et al., 2014, Alhumaydhi et al., 2020, Engelward et al., 1996, Klapacz et al., 2010, Allocca et al., 2017, Meira et al., 2009, Calvo et al., 2013, Calvo et al., 2016, Allocca et al., 2019). However, prior studies have been almost exclusively focused on model methylating agents, for which human exposure is unlikely. Here, we have turned our attention to an environmental contaminant that is a major public health concern, *N*-nitrosodimethylamine (NDMA). NDMA is potently genotoxic and carcinogenic in animals (Dass et al., 1998, Dass et al., 1999, Nishikawa et al., 1997, Peto et al., 1991, Vesselinovitch, 1969, Weghorst et al., 1989), and has been classified as an IARC Group 2A probable human carcinogen (IARC, 2010). Its genotoxicity is dependent upon metabolic activation by CYP2E1, which produces the highly reactive methyldiazonium ion (Haggerty and Holsapple, 1990, Lee et al., 1996, Sohn et al., 1991), which reacts with DNA to create 3MeA, *O*⁶-methylguanine (*O*⁶MeG), and other DNA lesions (Swenberg et al., 1991, Pegg and Hui, 1978, Souliotis et al., 1998, Beranek, 1990). Importantly, irresponsible disposal of industrial waste has resulted in massive levels of NDMA contamination in the environment. For example, ineffective containment of more than 20 million gallons of chemical waste at the Olin Chemical Superfund Site led to NDMA contamination of the local drinking water supply. NDMA is also present in food, including processed meat, which was designated an IARC Group 1 known human carcinogen in 2015 (IARC, 2015). It also contaminates many public water supplies as a result of certain water treatment processes (Richardson, 2003, Kimoto, 1980, Sedlak et al., 2005, Mitch and Sedlak, 2004). Furthermore, a recent public health crisis has emerged due to high levels of NDMA contamination in commonly used drugs taken by millions of people (Pottgard et al., 2018, Scherf-Clavel et al., 2019, Sorgel et al., 2019, Tsutsumi et al., 2019, Parr and Joseph, 2019). While *O*⁶MeG lesions are known to be mutagenic and have been intensely studied, 3MeA lesions are also highly consequential, but less well-studied. While studies are underway to interrogate the contributions of *O*⁶MeG to NDMA-induced disease, here we were able to isolate the specific consequences of unrepaired 3MeA and its downstream repair intermediates by modifying the levels of the enzyme responsible for its excision, namely, AAG.

While AAG has several substrates, 3MeA is among the most consequential, because its other methylated substrates are either relatively benign (*e.g.*, 7MeG) or far less prevalent than 3MeA (*e.g.*, 3MeG) (Strauss et al., 1975). Although 7MeG can depurinate to form abasic sites ($t_{1/2} = \sim 69\text{h}$) (Gates et al., 2004), these would arise gradually and so the biological impact of an AAG deficiency is likely driven by 3MeA. This single aberrant methyl group inhibits replicative polymerases, possibly due to disruption of critical hydrogen bonding between the polymerase and the N3 position of adenine that are required for stabilization and extension (Plosky et al., 2008, Doublet and Ellenberger, 1998, Larson et al., 1985). Cells have two major responses for tolerating replication blocking lesions, namely, recruitment of translesion polymerases and induction of homologous recombination (HR). *In vitro* studies indicate that while lower fidelity translesion synthesis (TLS) polymerases can replicate past potentially toxic 3MeA lesions, the process is significantly mutagenic (Plosky et al., 2008, Johnson et al., 2007, Yoon et al., 2017, Monti et al., 2010). Alternatively, polymerase stalling can stimulate homologous recombination (HR) (Ait Saada et al., 2018, Lambert et al., 2010, Yeeles et al., 2013, Marians, 2018, Engelward et al., 1996). Although HR is often considered error-free, misalignments and strand slippage during HR can lead to large-scale sequence rearrangement mutations, including insertions, deletions, translocations, and loss of heterozygosity that promote cancer (Gupta et al., 1997, Lambert et al., 2010, Lambert et al., 2005, Piazza et al., 2017, Shao et al., 1999, Pal et al., 2011, Strout et al., 1998, Aissi-Ben Moussa et al., 2009, Bishop and Schiestl, 2001, Kolomietz et al., 2002, Ogiwara et al., 2008, Haigis and Dove, 2003, Zhang et al., 2011, Cui et al., 2011, Anwar et al., 2017). Given that 3MeA can induce TLS and HR, a focus of this particular study is on susceptibility of mice to 3MeA-driven point mutations and large-scale sequence rearrangements. Interestingly, the predicted effects of *Aag* overexpression are very different. High levels of AAG activity cause an increase in the levels of SSBs (Alhumaydhi et al., 2020, Allocca et al., 2019, Parrish et al., 2018, Margulies et al., 2017) that cannot be bypassed by polymerases. Indeed, SSBs promote replication fork breakdown, leading to one-ended double strand breaks (DSBs) that can both signal for cell death and trigger HR.

To learn about the progression from exposure-induced DNA damage to disease for an environmentally relevant hazardous chemical, we compared *Aag*^{-/-} and *AagTg* mice for initial DNA and tissue damage, mutations, and downstream cancer in the liver (where NDMA is metabolically activated). We found that *Aag*^{-/-} mice have a dramatic increase in mutations and cancer in the liver compared to WT mice. In contrast, mutations and cancer were significantly *reduced* in *AagTg* mice relative to WT mice. Prior studies have linked AAG-induced SSBs to cytotoxicity (Calvo et al., 2013, Allocca et al., 2017, Allocca et al., 2019, Margulies et al., 2017), and so cell death may prevent mutant cells from surviving and inducing cancer. While seemingly beneficial, the cost is that there is increased tissue damage and lethality. Interestingly, the suite of responses uncovered in *Aag*^{-/-} and *AagTg* mice also occur in WT mice, but to a lesser extent. Thus, cells with balanced BER still contend with the consequences of both unrepaired 3MeA and its downstream SSBs, but they are ultimately protected from the extreme adverse outcomes observed in mice with either too little or too much *Aag* expression. Taken together, this study points to reduced AAG activity as a risk factor for NDMA-induced liver cancer, whereas elevated AAG activity increases risk for toxicity-driven phenotypes. As people are quite variable in their AAG levels (Calvo

et al., 2013, Crosbie et al., 2012, Hall et al., 1993), this study points to AAG activity levels as a potentially deciding factor for disease susceptibility for people exposed to NMDA.

RESULTS

NDMA is potently point mutagenic, particularly in AAG-deficient mice

While it is known that DNA damage can induce mutations that cause cancer, the relative impact of an unrepaired DNA base adduct versus its downstream intermediates on point mutations had not been explored previously. We leveraged the *gpt* delta transgenic mouse model developed by the Nohmi laboratory (Nohmi et al., 1996), which enables quantification of point mutations via heterologous gene expression in *E. coli*. Briefly, these mice contain multiple copies of the bacterial nucleotide salvage pathway guanine phosphoribosyltransferase (*gpt*) gene, which confers sensitivity to 6-thioguanine. DNA extracted from *gpt* delta mouse tissues can be packaged into phage and transformed into *E. coli*, and bacteria that receive a mutant *gpt* gene can form colonies on 6-thioguanine selection plates. The frequency of resultant colonies thus correlates to the number of mutations that occurred in the mouse.

We studied point mutations in livers from WT, *Aag*^{-/-} and *AagTg* mice exposed to 10.5 mg/kg NDMA, injected intraperitoneally in mice in a split dose at 8 (3.5 mg/kg) and 15 days old (7 mg/kg), a dosing regimen that was previously shown to cause liver and lung tumors in C57B16 mice (Dass et al., 1998) (Figure S1). We extracted genomic DNA from livers 10 weeks after exposure, a timepoint at which there was no histological evidence of neoplastic changes (Figure S2), thus reducing the possibility that mutations were caused by a tumor-associated mutator phenotype. We observed increased levels of hepatocellular degeneration and hypertrophy at 10 weeks in all mice treated with NDMA, but these did not differ significantly between NDMA-treated groups (Figure S2). When we analyzed point mutations, we observed a significant increase in WT mice (Figure 1A), consistent with the ability of NDMA to create point mutagenic DNA damage (Pegg and Hui, 1978, Souliotis et al., 1998, Swenberg et al., 1991, Beranek, 1990). *Aag*^{-/-} mice, on the other hand, have a greatly enhanced susceptibility to NDMA-induced mutations (Figure 1A) which is consistent with evidence that replication past 3MeA lesions via TLS polymerases leads to the insertion of incorrect nucleotides (Monti et al., 2010, Johnson et al., 2007, Plosky et al., 2008).

Excision of 3MeA by AAG produces an abasic site, which can inhibit polymerases (Pages et al., 2008), and TLS bypass of abasic sites can result in point mutations (Haracska et al., 2001, Zhang et al., 2000). We therefore hypothesized that mice overexpressing *Aag* would show an increase in point mutations compared to WT mice due to increased abasic sites. However, *AagTg* mice showed a significantly *lower* frequency of point mutations than WT, and far lower than that of *Aag*^{-/-} mice (Figure 1A). This result is consistent with AAG-mediated abasic sites being quickly processed by APE1 into SSBs, which cannot be mutagenic via TLS.

NDMA induces phosphorylation cascades indicative of HR induction

When replication forks encounter lesions that inhibit progression, such as SSBs or replication-blocking lesions, the stalled or broken fork be restored by HR. However, mis-insertion during replication fork repair can lead to large-scale sequence rearrangements that are known to drive cancer (Strout et al., 1998, Pal et al., 2011, Aissi-Ben Moussa et al., 2009, Bishop and Schiestl, 2001, Kolomietz et al., 2002, Ogiwara et al., 2008, Haigis and Dove, 2003). We therefore investigated the possibility that NDMA is recombinogenic *in vivo*. Specifically, since DNA damage induces a DNA damage response (DDR) characterized by activation of ATM and ATR kinases (Matsuoka et al., 2007), we analyzed the putative ATM/ATR substrate motif-specific phosphoproteome of control and NDMA-exposed WT mice. Analysis shows activation of DDR 24h post-exposure, consistent with stress responses to DNA damage (Figure 1B and Table S1). In particular, we observed phosphorylation of proteins associated with DSB recognition (blue font), including at the known DNA damage-regulated S732 site of MDC1 (Matsuoka et al., 2007), the ATM autophosphorylation site S1987 (Daniel et al., 2008, Pellegrini et al., 2006), and as yet uncharacterized sites on the DSB recognition proteins 53BP1 (S579) and NBN (S508). We also found that NDMA induced phosphorylation at sites associated with replication stress and DNA damage (red font), including H2AX S140 (Mazouzi et al., 2016), MCM6 S704 (Mazouzi et al., 2016), and MCM2 S108 (Cortez et al., 2004, Charych et al., 2008). Finally, we identified increased phosphorylation of HR proteins at known activation sites (green font), including RAD50 S635 (Gatei et al., 2011) and UIMC1 (aka RAP80) S402 (Yang et al., 2018, Matsuoka et al., 2007, Wang et al., 2007) as well as at uncharacterized sites on the HR proteins BRCA1 (S1422), RAD51c (S347), and ABRAXAS1 (S48). Notably, the S1422 site on mouse BRCA1 has high sequence similarity to the human BRCA1 site S1423, which is important for HR activity (Beckta et al., 2015), the G2/M checkpoint (Xu et al., 2001), and acetylation of p53 (Li et al., 2019). Given this molecular evidence that NDMA induces DNA damage, replication stress, and HR, we next turned our attention to a phenotypic readout for HR events.

NDMA lesions repaired by AAG are more recombinogenic than their downstream repair intermediates

To more directly assess HR, we performed a functional assay for genetic sequence rearrangements 10 weeks post-exposure. The RaDR transgenic mouse model enables evaluation of the frequency of mutagenic recombination events in whole-mount tissues (Sukup-Jackson et al., 2014). The RaDR transgene (shown in Figure 1C) contains a direct repeat of truncated EGFP expression cassettes at the ubiquitously expressed *Rosa26* locus (Sukup-Jackson et al., 2014, Soriano, 1999). Upon recombination between the cassettes, full-length EGFP cDNA can be produced and expressed, creating a fluorescent signal (as shown in Figure S3). The frequency of this specific mutagenic recombination event can be readily visualized in whole-mount tissue where fluorescent foci are indicative of recombination events (Figures 1D and S3). To achieve rapid and unbiased quantification, we developed a machine learning algorithm to enumerate fluorescent foci in whole-mount liver tissue and normalize to tissue area (see STAR methods and Figure S4). Here, we demonstrate that NDMA is highly recombinogenic *in vivo* (Figure 1D and E).

As SSBs are known to cause fork breakdown, which stimulates HR, we predicted that *AagTg* mice would be highly susceptible to NDMA-induced recombination events. Unexpectedly, *AagTg* mice showed a strong *reduction* in HR events compared to WT mice (Figure 1D and E). This observation raises the possibility that damaged cells are also susceptible to cell death as well as HR. In contrast to the *AagTg* mice, *Aag*^{-/-} mice have a significant increase in susceptibility to mutagenic recombination compared to WT (Figure 1D and E). This result is consistent with prior *in vitro* studies showing that 3MeA is recombinogenic (Engelward et al., 1996, Hendricks et al., 2002, Engelward et al., 1998), and with the possibility that 3MeAs are less toxic than SSBs, allowing for more mutant cells to survive.

DNA strand breaks and chromosomal instability are modulated by AAG activity

Given that both replication-blocking lesions and SSBs can cause fork breakdown, we next asked if AAG modulates the levels of DSBs. Phosphorylation of the histone variant H2AX at Ser139 (γ H2AX) occurs at sites of replication stress, most significantly in response to DSBs (Bekker-Jensen and Mailand, 2010, Scully and Xie, 2013, Stucki et al., 2005, Ward and Chen, 2001, Chanoux et al., 2009), as well as in response to SSBs (Katsube et al., 2014). We therefore approximated the frequency of cells that harbor an increase in strand breaks 24h post-exposure by quantifying cells with five or more γ H2AX foci (Figure 2A, white arrow). In WT mice, we observed a significant increase in the levels of cells with increased levels of γ H2AX foci, consistent with NDMA-induced strand breaks (Figure 2C). Consistent with the lack of glycosylase activity in *Aag*^{-/-} mice, we observed fewer cells with γ H2AX foci relative to WT mice (Figure 2C).

We next quantified cells with γ H2AX foci in livers of *AagTg* mice (Figure 2C). We observed comparable levels of γ H2AX-positive cells for *AagTg* mice compared to WT (Figure 1E), despite previous studies showing increased induction of SSBs following alkylating exposures in these mice (Allocca et al., 2019). A potential explanation for these observations is that excess SSBs cause such a strong DNA damage response that cells die instead of undergoing mutagenesis. To explore this possibility, we evaluated pan-nuclear staining of γ H2AX (Figure 2A, red arrows), which occurs when there is an overwhelming amount of DNA damage (Moeglin et al., 2019, Baritaud et al., 2012, Ewald et al., 2007). Although we observed similar levels of pan-nuclear staining for all genotypes (Figure 2D), during our analysis, we also observed super-bright pan-nuclear γ H2AX staining, which has previously been shown occur in apoptotic cells due to cytotoxic damage in S-phase (Moeglin et al., 2019, Ewald et al., 2007, Huang et al., 2004) (Figure 2A, red asterisk). Using ImageJ (NIH), a high threshold for pixel intensity (combined with exclusion of cells with subnuclear foci) was applied to identify cells with exceptionally intense pan-nuclear staining (see STAR methods). Interestingly, *AagTg* livers showed a dramatic increase in the frequency of super-bright pan-stained nuclei, whereas WT and *Aag*^{-/-} showed only slight increases (Figure 2E). These results indicate that *AagTg* cells have extremely high levels of DNA damage that potentiate cell death, which would be consistent with reduced mutant cells at 10 weeks.

In addition to induction of γ H2AX, DSBs can also lead to the formation of micronuclei (MN) in dividing cells (an example of a hepatocyte with MN is shown in Figure 2B). We observed a significant increase in MN in NDMA-treated WT mice, a result that is consistent with DSBs during cell division (Figure 2F). (Note that division was similar among NDMA-treated groups as evidenced by Ki67; Figure S5.) Interestingly, *Aag*^{-/-} mice showed similar levels of MN induction as WT. In contrast, the *AagTg* mice had significantly higher frequencies of MN than WT, consistent with the observation that these mice are susceptible to overwhelming amounts of DSBs. Since overwhelming and persistent DNA damage can be cytotoxic, we next analyzed the frequency of cell death *in vivo*.

NDMA causes hepatotoxicity in mice with imbalanced BER

To determine the acute hepatotoxic effects of NDMA in mice, we evaluated apoptosis and histopathological changes in livers 24 hours after the second NDMA injection. Consistent with induction of cytotoxic DNA damage, we observed an increase in apoptotic events in all NDMA-treated livers, with significantly more apoptosis in *Aag*^{-/-} compared to WT and the highest degree in *AagTg* livers (Figure 3A). Histologically, all groups of NDMA-treated mice had changes consistent with hepatocellular necrosis and degeneration (Figure 3B and C), which were often noted in centrilobular regions (Figure S6B, D, F, H, J, and L). Remarkably, *AagTg* livers exhibited significantly higher histological scores of centrilobular necrosis compared to both WT and *Aag*^{-/-} (Figure 3B). The centrilobular lesions in *AagTg* livers contained multiple necrotic hepatocytes, characterized by increased cytoplasmic eosinophilia and nuclear fragmentation, which were surrounded by vacuolated eosinophilic hepatocytes (degeneration) and low numbers of leukocyte infiltrates at the periphery (Figure S6J and L). *Aag*^{-/-} mice had increased hepatocellular necrosis and degeneration compared to WT mice (Figure 3B and C), with multifocal areas of hepatocellular degeneration mixed with an increased number of necrotic hepatocytes and inflammatory cell infiltrates (Figure S6F and H). WT livers showed multifocal areas of mild hepatocellular degeneration mixed with foci of single cell necrosis in centrilobular zones (Figure S6B and D). Together, these lesions were consistent with previous studies in laboratory rodents exposed to NDMA (Tolba et al., 2015, Barnes and Magee, 1954, George et al., 2019).

Hepatocellular necrosis and degeneration are well-known for their ability to elicit inflammation (Sachet et al., 2017, Westman et al., 2019, Iyer et al., 2009). Analysis shows that the cumulative inflammation score, representing all zones of the hepatic lobules (centrilobular, midzonal, and portal), was markedly enhanced in all mice treated with NDMA (Figure 3D). (Inflammation scores for centrilobular and midzonal regions are shown in Figure S6M and N). Livers from NDMA-treated *Aag*^{-/-} and *AagTg* mice had significantly higher inflammation scores than those of WT animals (Figure 3D). These results suggest that inflammatory cell recruitment is likely mediated by mechanisms dependent on NDMA hepatotoxicity and AAG function. In addition, the significant increase in cytotoxicity and inflammation in *Aag*^{-/-} livers compared to WT supports the hypothesis that unrepaired blocking lesions can produce an overwhelming DNA damage response, leading to toxicity that drives inflammation. It is noteworthy, however, that *Aag*^{-/-} hepatocytes are less susceptible to cytotoxicity, inflammation, and induction of super-bright

pan-nuclear γ H2AX and MN than *AagTg*, suggesting that blocking lesions are less toxic than SSBs.

***AagTg* mice are susceptible to NDMA-induced lethality**

In addition to acute hepatotoxic lesions, we also observed diminished survival in NDMA-treated *AagTg* mice. Over 12% of *AagTg* mice died within two weeks of injection, whereas nearly all WT and *Aag^{-/-}* mice survived exposure to NDMA (>98%; Table 1). Previous work has shown that acute toxic effects of NDMA occur predominantly in the liver, with minimal evidence of toxicity in other organs in the first few days after exposure (Barnes and Magee, 1954). Thus, elevated animal lethality supports a model wherein *AagTg* livers are particularly sensitized to NDMA toxicity. Our observation that imbalanced BER is lethal is supported by previous studies showing that *AagTg* mice have a significantly lower LD₅₀ for alkylating agents compared to WT (Calvo et al., 2016) and *Aag^{-/-}* mice (Calvo et al., 2013).

AAG activity reduces susceptibility to liver cancer

To learn about the impact of AAG levels on cancer risk, we let mice age for ~10 months to allow time for liver tumors to develop (the average age at necropsy of each saline treatment group was between 10.4–10.6 months, and the average age of each NDMA treatment group was 10.0–10.2 months). We observed a high incidence of macroscopic tumor induction in WT mice, with 67% of NDMA-treated animals developing visibly evident tumors (Table 2). Tumor multiplicity was generally low, wherein no mouse developed more than 5 visible tumors and the median number of tumors was 1 (Figure 4 and Table 2).

Aag^{-/-} mice developed significantly more grossly visible tumors than WT mice. In total, 86% of *Aag^{-/-}* mice developed tumors, and the median number of tumors per mouse was significantly higher (4.5 tumors/mouse; Table 2). Considering these data in the context of early phenotypes, it becomes apparent that 3MeA is highly mutagenic and only moderately cytotoxic, which is consistent with survival of cells that acquire tumorigenic mutations. In striking contrast, we observed reduced tumor induction in *AagTg* mice compared to WT (and far lower tumor induction compared to *Aag^{-/-}*; Table 2 and Figure 4). Less than half of *AagTg* mice developed any macroscopic tumors, and therefore the median number of tumors was 0 (Table 2). Of note, diminished induction of mutant cells in *AagTg* mice correlated with reduced susceptibility to tumorigenesis.

Integration of discrete endpoints reveals biomarkers upstream of cancer and lethality

To gain an integrated understanding of how different phenotypes are related to one another, we combined data sets, as shown in Figure 5. Starting from the top and working clockwise, we have plotted key observations from our experiments in chronological order. These include DNA damage (γ H2AX foci), replication stress (super-bright pan-nuclear γ H2AX), chromosomal instability (micronuclei), cytotoxicity (apoptosis), animal lethality, point mutations, recombination events, and tumor induction. Medians or means were normalized to the highest scoring group for that endpoint (e.g., NDMA-treated *Aag^{-/-}* mice developed the most tumors [median = 4.5], so all tumor burden medians were normalized to *Aag^{-/-}* NDMA). Light-colored lines show the results for saline-treated mice, and dark colors show the results for NDMA-treated groups.

Although markers of genotoxicity and animal lethality in NDMA-treated *Aag*^{-/-} mice were lower than or equivalent to those of WT mice, cytotoxicity was significantly increased, and there was very strong induction of mutations and tumors. In stark contrast, overexpression of *Aag* led to poor outcomes shortly after NDMA exposure (including genotoxicity, cytotoxicity, and lethality), and mutations and cancer are low. It is remarkable that for WT mice, the integrated toxicity-related phenotypes (on the right side) as well as the integrated mutagenicity/cancer phenotypes (on the left side) are both reduced compared to *Aag*^{-/-} and *AagTg* mice. In fact, response patterns in WT mice show some similarities to both the *Aag*^{-/-} and the *AagTg* mice, which is consistent with NDMA exposure both saturating AAG excision capacity (leading to persistent 3MeA) while simultaneously causing stress to the downstream BER pathway (leading to increased SSBs and DSBs). Ultimately, the ability to both excise replication blocking lesions and complete the BER pathway mitigates the extreme adverse effects of both replication blocks and strand breaks.

DISCUSSION

In this work, we have explored the relationships of two fundamentally different classes DNA damage with cancer and lethality, namely lesions that block replication and strand breaks. By varying *Aag* expression, we were able to specifically probe the consequences of unrepaired replication-blocking 3MeA and SSBs formed as BER-intermediates. With a focus on NDMA, a carcinogen that contaminates water, food, and drugs, we found that AAG has an enormous impact on whether cells will survive DNA methylation damage and whether they will eventually develop mutations and cancer. Given that individuals are known to vary in AAG activity, this study points to AAG as being a key variable that dictates the health impact of DNA methylation damage. Methylating agents are not only important environmental contaminants, but they are also used as chemotherapeutic agents to treat cancer. As such, the results of this work have broad relevance to public health as well as to personalized medicine for cancer patients.

We aimed to integrate across multiple phenotypes over time in order to uncover biomarkers with predictive potential for downstream cancer. By presenting the integration of phenotypes in the radar plots, a holistic perspective on biological responses in WT, *Aag*^{-/-} and *AagTg* mice is gained. We found that phenotypes related to toxicity are high in the *AagTg* mice, while downstream mutations and cancer endpoints are equivalent to or lower than WT. In contrast, the *Aag*^{-/-} mice have results heavily skewed toward mutations and cancer with weaker indicators of genotoxicity. These results support a model wherein blocking lesions repaired by AAG are moderately cytotoxic but highly mutagenic, whereas BER intermediates (e.g., SSBs) are highly toxic, reducing survival of damaged cells and suppressing the development of mutations, but at the cost of increased lethality. Interestingly, strand break-induced toxicity appears to be protective against cancer, consistent with a broad literature showing that disabling apoptosis signaling accelerates cancer (Norbury and Zhivotovsky, 2004, Foster et al., 2012, Lowe and Lin, 2000, Roos and Kaina, 2013). Notably, WT mice show responses that are consistent with both unrepaired 3MeA and SSBs, but each to a lesser extent. Thus, the ability to initiate repair is key to cancer prevention, and completion of the BER pathway is key to prevention of toxicity.

The results of these experiments are consistent with previous studies showing reduced toxicity from 3MeA relative to BER intermediates (Sobol et al., 2003, Meira et al., 2009, Calvo et al., 2013, Margulies et al., 2017, Allocca et al., 2019, Ebrahimkhani et al., 2014, Kisby et al., 2009). In fact, knockout of *Aag* has been shown to reduce SSBs (Ensminger et al., 2014) and protect against alkylation-induced toxicity and degeneration in the retina and cerebellum (Meira et al., 2009, Allocca et al., 2019, Calvo et al., 2013, Margulies et al., 2017), and overexpression of *Aag* results in elevated levels of SSBs (Margulies et al., 2017) and sensitizes cells to alkylation-induced toxicity (Hendricks et al., 2002, Ibeanu et al., 1992). In terms of cancer, *Aag*^{-/-} mice have been found to be more susceptible to exposure-induced mutations and tumors in the colon (Calvo et al., 2012, Meira et al., 2008, Wirtz et al., 2010, Fahrer et al., 2015). Interestingly, however, the specific biological consequences of AAG appear to vary by context. For example, both overexpression and knockout of *Aag* have been associated with chromosomal aberrations in mammalian cell culture (Coquerelle et al., 1995, Ensminger et al., 2014, Kaina et al., 1993, Engelward et al., 1998, Ibeanu et al., 1992, Engelward et al., 1996). Additionally, we have previously observed that knockout of *Aag* protects against methylation-induced immune cell infiltration and inflammation in the retina, whereas here we observed increased immune cell infiltration in the NDMA-treated liver of *Aag*^{-/-} mice, pointing to tissue-specific differences. We have also shown that treatment of *Aag*^{-/-} mice with the alkylating agent methyl nitrosourea (which causes the same lesions as NDMA) did not significantly induce sequence rearrangement mutations in the pancreas (Kiraly et al., 2014), suggesting tissue-specific differences in mutagenesis, as has previously been described (Loktionov et al., 1990, Schmezer et al., 1994, Mientjes et al., 1998, Wang et al., 1998). One possibility is that TLS is less efficient in the liver relative to the pancreas (exacerbating the consequences of blocking lesions). Indeed, TLS capacity has been shown to be highly variable depending on cell type (Cruet-Hennequart et al., 2009, Makridakis and Reichardt, 2012, Lange et al., 2011).

An unexpected pattern revealed by our analyses was the lack of consistency between γ H2AX staining and recombination events, despite the fact that DSBs are repaired by HR during S/G2. Interestingly, for *AagTg* mice (wherein increased SSB-induced replication fork breakdown can be restored by mutagenic HR; Figure S7A), we observed similar induction of γ H2AX foci as WT, leading one to predict similar degrees of HR induction in WT and *AagTg* mice. However, *AagTg* mice showed a significantly *reduced* frequency of cells harboring HR-driven mutations compared to WT. Analyses of super-bright pan- γ H2AX staining (indicative of toxic replication stress), MN induction, apoptosis, and necrosis all suggest that damaged cells are being eliminated rather than surviving with mutations. On the other hand, livers from *Aag*^{-/-} mice showed significantly reduced γ H2AX staining compared to WT, and yet they developed significantly more HR-driven mutations. The susceptibility of *Aag*^{-/-} mice to mutagenic recombination may therefore reflect DSB-independent HR events. While several studies have linked replication blocking lesions to HR through an endonuclease that creates DSBs (Saugar et al., 2013, Willis and Rhind, 2009, Hanada et al., 2006, Hanada et al., 2007), direct evidence of blocking lesions leading to fork breakdown and free DSB ends is lacking, in part because the predominant method for studying so-called blocked replication forks is to deplete cells of nucleotides, which is quite different from inducing damage that inhibits polymerases. Indeed, blocking lesions are

known to induce template switching (Ait Saada et al., 2018, Lambert et al., 2010, Mariani, 2018), and our data suggest that this is likely the dominant response to blocking lesions. In the case of the direct repeat HR substrate used for these studies, fork reversal (caused by leading strand blockage) may lead to misalignments that reconstitute the full-length EGFP cDNA (Figure S7B). Alternatively, lagging strand blockage can be bypassed by invasion of the sister chromatid, and misalignment during this process can also restore full-length EGFP (Figure S7C).

An exciting aspect of this study is that the combination of *gpt* delta and RaDR transgenes enables analyses of both point mutations and mutagenic recombination events within the same tissues. RaDR mutations can be evaluated by fluorescent microscopy on fresh tissue in mere minutes, and following imaging, the tissues can be flash frozen for subsequent *gpt* point mutation analyses. Using our dual detection approach, we show that conditions that promote point mutations also promote sequence rearrangements, an observation that has been suggested by many diverse studies but has proven difficult to demonstrate directly. While the RaDR and *gpt* delta assays cannot capture all possible genetic alterations that may drive cancer, such as chromosomal aberrations, they provide important information about two major classes of mutations. Importantly, the results of this study show strong predictive capacity of RaDR and *gpt* mutation assays for cancer risk, suggesting these assays may serve as effective surrogates for time- and resource-intensive carcinogenicity studies, especially for DNA damaging agents. Furthermore, results indicate that genotoxicity analyses, such as γ H2AX and MN, are not as effective in predicting cancer risk as analyses of mutations, and may even be misleading if not combined with analyses of toxicity.

A major challenge in chemotherapy is the risk of mutations that drive secondary cancers (Choi 2014). Ideally, a drug or combination of drugs would be toxic without being mutagenic. The approaches described here present an interesting opportunity to optimize cancer chemotherapeutics by integrating multiple early stage biomarkers predictive of both toxicity and downstream cancer. Evaluation of mutagenicity with RaDR;*gpt* mice in combination with analyses of DNA damage (*e.g.*, γ H2AX and MN) and toxicity may prove to be an effective strategy for optimizing treatments so as to avoid secondary cancers before going to clinical trials. This is particularly important for childhood cancer therapies, for which secondary cancers can arise over a decade after treatment.

In addition to replication fork breakdown-associated DSBs that signal apoptosis, prior studies show that overactivity of PARP is a significant modulator of AAG-driven toxicity due to increased strand breaks and PARP-1 hyperactivation (Alhumaydhi et al., 2020, Allocca et al., 2017, Allocca et al., 2019). PARP-1 stimulates repair of SSBs by polymerizing ADP-ribose from NAD⁺, so an excess of DNA damage causes NAD⁺ depletion and a form of programmed necrotic cell death termed parthanatos (Yu et al., 2002, Zhao et al., 2018, Xu et al., 2006). We have previously shown that *AagTg* mice experience elevated cytotoxicity and tissue degeneration from DNA alkylating treatments in the cerebellum, retina, spleen, thymus, bone marrow, and pancreas (Calvo et al., 2013, Allocca et al., 2017, Allocca et al., 2019, Margulies et al., 2017), and that this is often dependent on PARP-1. Indeed, histopathology of NDMA-treated *AagTg* livers showed significantly elevated necrosis over that of WT and *Aag*^{-/-} livers. It is also noteworthy that

PARylation by PARP-1 facilitates the recruitment of several proteins involved in HR (Haince et al., 2008, Bryant et al., 2009, Li and Yu, 2013); as a result, NAD⁺ depletion in *AagTg* cells may have prevented effective HR, leading to the observed reduction in HR-driven mutations in those mice. Since high levels of cytotoxicity drive degenerative diseases and aging, individuals with high AAG activity may be at elevated risk for such pathologies. In this context, it is interesting to note that *AagTg* mice have approximately 6-fold higher AAG activity than WT in the liver (Calvo et al., 2013), whereas AAG activity can vary by as much as 20-fold among people (Calvo et al., 2013, Crosbie et al., 2012, Hall et al., 1993), calling attention to the biological relevance of this study.

The work presented here uncovers a variety of insights regarding human susceptibility to disease. NDMA contamination is widespread, and there are many sources of human exposure. Since people have been shown to vary substantially in AAG activity (Chaim et al., 2017, Calvo et al., 2013, Crosbie et al., 2012, Leitner-Dagan et al., 2012), our research may provide a means of stratifying exposed populations into low- and high-risk categories for different adverse health outcomes. For example, DNA methylating agents are often used for cancer chemotherapy, and so knowledge of the levels of AAG in a tumor can be used for precision medicine, since high levels of AAG would predict effective cytotoxicity, whereas low AAG would point to increased mutations (and potentially more aggressive tumors). Indeed, studies have shown that some individuals have very low levels of AAG activity in peripheral blood mononuclear cells (Calvo et al., 2013), raising the possibility that these individuals are more vulnerable to methylation-induced cancers. Future epidemiological studies will be very interesting in this context. Importantly, from the public health perspective, novel technologies that enable screening of people for their AAG activity (Nagel et al., 2014, Chaim et al., 2017) are paving the way for precision prevention. Taken together, the results of this study provide a basis for advancements in predicting outcomes of exposure to DNA alkylating agents that promise to help in both treating and preventing cancer.

Limitations of the study

A limitation of this study is that the analysis of the phosphoproteome did not include *Aag*^{-/-} or *AagTg* mice, as these studies are currently underway. We anticipate that results will be very interesting, since knowing how AAG modulates cell signaling will add to our understanding of the very earliest responses, for which some may play key roles in setting into motion the sequence of events that ultimately shapes disease outcome. Another potential limitation is that EGFP expression may have negative biological consequences due to fluorophore-associated oxidative stress (Ganini et al., 2017). However, the strong parallels between point mutations and RaDR mutations suggests that using EGFP expression as a marker for mutant cells does not significantly affect the results of these studies.

Importantly, the analyses presented here grouped equal numbers of males and females of the same genotype. However, it is known that males and females differ in susceptibility to alkylation damage (Allocca et al., 2017, Allocca et al., 2019, Likhite et al., 2004) and liver cancer (Hassan et al., 2017, Naugler et al., 2007, Rao and Vesselinovitch, 1973). A brief report on sex differences observed in these experiments is in preparation, but further studies

of sex-dependent differences in *Aag*^{-/-} and *AagTg* mice will help define interindividual variability in responses to NDMA-induced health outcomes.

Additional studies of NDMA in other tissues and at lower doses will help to further uncover the biological consequences of NDMA in animals with varied AAG activity. NDMA is mutagenic in the lungs and kidneys of mice exposed by i.p. injection (Nishikawa et al., 1997, Suzuki et al., 1996), and we have previously shown that alkylation-induced toxicity is both tissue- and AAG-dependent (Calvo et al., 2013, Allocca et al., 2019). Interestingly, higher levels of AAG activity were observed in smokers and individuals with lung cancer (Crosbie et al., 2012, Hall et al., 1993, Leitner-Dagan et al., 2012), raising the possibility that the consequences of high AAG may be quite different in the lung compared to the liver. Furthermore, the exposure conditions used in this study differ substantially from the typical human experience, as people tend to be exposed to NDMA in lower doses over long periods of time. It is noteworthy that in yeast, the AAG homolog Mag1 protects against methylation-driven HR even at non-toxic doses (Hendricks et al., 2002), suggesting that AAG may modulate the impact of NDMA on sequence rearrangements even under long-term low-dose conditions. Future studies on the impact of NDMA on different tissues and at long-term low-dose exposures conditions are certainly warranted in order to better understand the potential for gene-environment interactions to modulate the health consequences of exposure to NDMA through water, food, or medications.

STAR Methods

RESOURCE AVAILABILITY

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Bevin Engelward (bevin@mit.edu).

Materials Availability—This study did not generate new unique reagents.

Data and Code Availability—The mass spectrometry proteomics data are available at the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2019) partner repository with the dataset identifier PXD021142. The RaDR foci counting algorithm is available on Github at https://github.com/dushanw/RPN_RC�_roiExtractor.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Animals—All experimental mice were on a C57BL6 genetic background. *RaDR*^{R/R}; *gpt*^{g/g} mice were created by crossing *RaDR*-GFP mice (B6.129S4(Cg)-*Gt(ROSA)26Sor*^{tm1(CAG-EGFP*)Bpeng}) (Sukup-Jackson et al., 2014) with *gpt* delta mice (Nohmi et al., 1996) (a gift from T. Nohmi). *RaDR*^{R/R}; *gpt*^{g/g}; *Aag*^{-/-} mice were generated by crossing *RaDR*^{R/R}; *gpt*^{g/g} and *Aag*^{-/-} mice (described previously (Engelward et al., 1997)). *RaDR*^{R/R}; *gpt*^{g/g}; *AagTg* were generated by crossing *RaDR*^{R/R}; *gpt*^{g/g} and *AagTg* mice (described previously (Calvo et al., 2013)). The mice were maintained in AAALAC-certified animal care facilities and provided standard food and water *ad libitum*. All animal procedures were performed according to the NIH Guide for the Care and Use of Laboratory

Animals and protocols approved by the Massachusetts Institute of Technology Committee on Animal Care.

METHOD DETAILS

NDMA synthesis—NDMA was prepared as previously described (Heath, 1961, He et al., 2019). Briefly, sodium nitrite in water was slowly added to a solution of dimethylaniline in water and acetic acid. After cooling, 10N NaOH was added and the solution was extracted four times with ether. The ether solution was dried over Na₂SO₄ and NDMA isolated by fractional distillation having a boiling point of 148-149°C. The pale yellow liquid was characterized by NMR and mass spectrometry: MS, ESI m/z, 75.0056 (M+H); ¹H 300 MHz NMR, CDCl₃ δ 3.06 (s, 3H,Me *cis*), 3.76 (s,3H,Me *trans*). The NMR assignments are in agreement with those reported for NDMA by Karabatsos and Taller (Karabatsos, 1964). Aliquots of NDMA were packaged in sealed ampules under Ar gas and stored at -20°C.

NDMA treatment—Litters of mice were designated for saline or NDMA treatment at birth. A total dose of 10.5 mg/kg NDMA diluted in saline was administered intraperitoneally over two separate injections, according to (Dass et al., 1998). One-third of the dose (3.5 mg/kg NDMA in saline, 10 µL volume) was given at 8 days of age, and the remaining two-thirds of the dose (7 mg/kg, 20 µL volume) was given at 15 days of age. Control mice were sham treated at the same timepoints with equivalent volumes of saline.

Mice were euthanized by asphyxiation with carbon dioxide according to AVMA guidelines and necropsied 24 hours (phosphoproteomics, immunostaining, and histopathology), 48 hours (flow cytometric micronucleus and proliferation), 10 weeks (mutations and histopathology), or 9 to 11 months (tumors) post-second injection. Whenever possible, equal numbers of males and females of each genotype and treatment group were analyzed for each endpoint. When data were collected from an excess number of males or females for an endpoint, individual data points were selected by random number generator for exclusion from analysis.

Gpt delta assay—Samples of liver tissue were collected after RaDR imaging, flash frozen in liquid nitrogen, and stored at -80°C until analysis (n = 5 males and 5 females from each group). Mutations in the *gpt* gene were identified by selection with 6-thioguanine (6-TG), as previously described (Nohmi et al., 1996, Chawanthayatham et al., 2017). Briefly, liver tissues were pulverized with a mortar and pestle with liquid nitrogen. Genomic DNA was extracted from approximately 25 mg of liver tissue using the RecoverEase DNA Isolation Kit (Agilent Technologies). The λ-EG10 phage were packaged *in vitro* from genomic DNA using Transpack packaging extract (Agilent Technologies). The λ-EG10 phage were then transfected into *Escherichia coli* YG6020 expressing Cre-recombinase, generating a 6.4-kb plasmid carrying the *gpt* and chloramphenicol acetyltransferase genes. These bacteria were cultured on selective media containing chloramphenicol and 6-TG or chloramphenicol alone. 6-TG resistance was confirmed by regrowth of colonies on plates containing chloramphenicol and 6-TG. The samples were processed and analyzed in a blinded fashion.

Phosphoproteomic analysis—Twenty-four hours after the second injection, animals were humanely euthanized and portions of livers were immediately excised, flash frozen in liquid nitrogen, and stored at -80°C until analysis (WT mice only; saline, one male and one female; NDMA, three females). Liver tissues were homogenized in ice-cold 8M Urea (Sigma) with three 10-second pulses. Proteins were processed, digested and desalted as described previously (Dittmann et al., 2019). Lyophilized peptide aliquots of 400 μg (of starting protein) were labeled with TMT10-plex labeling kits (Thermo Fisher). Phosphopeptides were enriched with a 2-step enrichment process consisting of immunoprecipitation (IP) followed by Fe-NTA-based immobilized metal affinity chromatography (IMAC). TMT-labeled samples were resuspended in IP buffer (100 mM Tris-HCl, 1% Nonidet P-40, pH 7.4) and incubated overnight with PTMScan Phospho-ATM/ATR Substrate Motif kit (Cell Signaling Technology). Peptides were eluted twice, each with 25 μL of 0.2% trifluoroacetic acid (TFA) for 10 minutes at room temperature followed by a secondary Fe-NTA-based IMAC to remove non-specifically retained non-phosphopeptides. High-Select Fe-NTA enrichment kit (Pierce) was used according to manufacturer's protocol with following modifications. After washing the Fe-NTA spin columns, beads were resuspended in 25 μL of binding washing buffer. Eluates from IP were incubated with Fe-NTA beads for 30 minutes. Peptides were eluted twice with 20 μL of elution buffer into a 1.7-mL microcentrifuge tube. Eluates were dried in SpeedVac until 1-5 μL of sample remained. Samples were resuspended in 10 μL of 5% acetonitrile in 0.1% formic acid and loaded directly onto an in-house packed analytical capillary column (50 μm ID x 10 cm) packed with 5- μm C18 beads (YMC gel, ODS-AQ, AQ12S05).

Liquid chromatography tandem mass spectrometry (LC-MS/MS) of phosphopeptides and crude lysate analysis was carried out on an Agilent 1260 LC coupled to a Q Exactive HF-X mass spectrometer (Thermo Fisher) as described previously (Dittmann et al., 2019). Raw mass spectra data files were processed with Proteome Discoverer version 2.2 (Thermo Fisher) and searched against the mouse SwissProt database using Mascot version 2.4 (Matrix Science). TMT reporter quantification was extracted using Proteome Discoverer. MS/MS spectra were searched with the following settings: mass tolerance of 10 ppm for precursor ions; 20 mmu for fragment ions; fixed modification for cysteine carbamidomethylation, TMT-labeled lysine, TMT-labeled peptide N-termini; dynamic modifications for methionine oxidation and phosphorylation of serine, threonine and tyrosine. Peptide spectrum matches (PSMs) were filtered according to following parameters: rank = 1, search engine rank = 1, mascot ion score > 20, isolation interference < 30%, average TMT signal > 1000. Peptides with missing values across any channel were filtered out. Phosphorylation sites were localized using ptmRS module (Taus et al., 2011) on Proteome Discoverer. PSMs with >95% localization probability were included for further analysis. Only peptides containing 'SQ' or 'TQ' sequence motif were included for final analysis. Peptide quantification was normalized with relative median values obtained from crude peptide analysis. Further data analysis was performed in Python (version 3.6) and MATLAB (R2016a).

RaDR analysis—Livers were collected from mice 10 weeks after the second NDMA injection (WT saline n = 12 males, 12 females; WT NDMA n = 11 males, 11 females;

Aag^{-/-} saline n = 11 males, 11 females; *Aag*^{-/-} NDMA n = 12 males, 12 females; *AagTg* saline n = 13 males, 13 females; *AagTg* NDMA = 9 males, 9 females). Freshly excised livers were held on ice in 0.01% trypsin inhibitor (Boston BioProducts) in PBS prior to imaging. The entire left lobe of the liver was secured between a glass slide and a cover slip. The dorsal surface of each liver was then imaged with a Nikon Eclipse Ti2 scanning microscope on the 2x objective in the FITC channel using an Andor Zyla 4.2 camera and NIS Elements software. A user-trained two-stage machine learning algorithm was used to identify and enumerate fluorescent foci within intact tissue (available on Github at https://github.com/dushanw/RPN_RCN_roiExtractor). Similar to our previous work (Wadduwage et al., 2018), we first identified potential regions (termed region proposals) that might contain foci, and then classified them into True Foci or False Regions (Figure S4A). Two deep convolutional neural networks (DCNNs) were used that were trained using 10 manually annotated images for both tasks. The first network (i.e. Region Proposal Network), segmented the foci-like regions. Then we used their locations to extract the corresponding image patches (i.e. region proposals). These region proposals were then fed to a second DCNN (i.e. Proposal Classifier Network) that classified them into either True Foci, or False Regions. The true foci locations were then listed and counted to get the final foci count. The 10 manually annotated training images comprised samples from each genotype and treatment group. All liver images were analyzed by the machine learning program based on parameters developed from training data. The number of fluorescent foci was normalized to the area of the liver in the image.

Histological analysis—Sections of liver were fixed in 10% buffered formalin, embedded in paraffin, and sectioned at 4- μ m thickness using a microtome, followed by hematoxylin and eosin (H&E) staining. Liver sections from 4 males and 4 females of each group (24h and 10-week timepoints) were scored by a board-certified veterinary pathologist blinded to sample identity. Specific lesions were graded with a numerical score from 0 to 4, in which 0 = normal, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe. The following hepatic lesions were graded: inflammation, hepatocellular degeneration, hepatocellular necrosis, nuclear enlargement (karyomegaly), foci of hepatocellular alteration, hepatic lipidosis, extramedullary hematopoiesis, Kupffer cell hyperplasia, Ito cell hyperplasia, bile duct hyperplasia/dysplasia, and fibrosis (Thoolen et al., 2010). Lesions for the liver scored as present (1) or absent (0) included hemorrhage and neoplasia. A total inflammation score for each liver was generated by combining individual scores of portal, midzonal, and centrilobular inflammation from each submitted section (Snider et al., 2018). Foci of altered hepatocytes were classified based on morphologic criteria reported by Thoolen and colleagues (Thoolen et al., 2010). Sections were examined using an Olympus BX41 microscope attached with an iKona digital camera and photographed.

γ H2AX staining and analysis—Formalin-fixed tissue sections (4 μ m) (n = 4 males and 4 females from each treatment group, 24h timepoint) were deparaffinized in xylenes, rehydrated, and subjected to heat-induced epitope retrieval (HIER) in citrate buffer pH 6.1 (Agilent). Sections were blocked with 5% bovine serum albumin (BSA) and 0.5% Tween 20 for 1 hour at room temperature, then incubated with an antibody for γ H2AX (1:200; Cell Signaling Technologies) in 1% BSA and 0.5% Tween 20 in PBS overnight at 4°C. Sections

were then washed and incubated with a secondary antibody conjugated to an AlexaFluor 488 probe (1:400; Invitrogen) for 1 hour at room temperature. Nuclei were counterstained with DAPI with ProLong Gold AntiFade (ThermoFisher). Stained tissue sections were imaged at 60x under DAPI and FITC filters using a Nikon Eclipse Ti2 microscope and an Andor Zyla 4.2 camera, with two independent regions randomly selected from each slide. A complete immunofluorescence staining protocol is available at <https://nextgen-protocols.org/protocol/staining-for-%ce%b3h2ax-in-paraffin-embedded-tissue-sections/>.

Cells containing 5 or more γ H2AX foci or pan-nuclear staining were manually annotated and enumerated in a blinded fashion. Super-bright pan-nuclear staining was determined with ImageJ (NIH) by setting a conservative pixel intensity threshold and excluding particles smaller than $10 \mu\text{m}^2$. Nuclei were identified by using Ilastik (Berg et al., 2019) and KNIME (University of Konstanz, Zurich, Switzerland) software to segment nuclei based on user-annotated training images. Segmented particles were counted in ImageJ for an approximate number of nuclei in the image, and the percentage of nuclei falling into each category (foci, pan-nuclear, super-bright pan-nuclear) was calculated. Data were collected for at least 1,300 nuclei from each mouse.

Caspase staining and analysis—Formalin-fixed tissue sections ($4 \mu\text{m}$) from 4 males and 4 females from each treatment group (24h timepoint, same mice as those analyzed for γ H2AX and histopathology) were deparaffinized in xylenes, rehydrated, and subjected to HIER in Buffer H, pH 8.8 (Thermo Scientific). After cooling, endogenous peroxidase was blocked with Peroxidazed 1 (Biocare Medical) for 5 minutes and slides were blocked in Background Sniper (Biocare Medical) for 15 minutes. Slides were then incubated with cleaved caspase-3 primary antibody (Cell Signaling Technology) for 60 minutes at room temperature, washed, and incubated with Rabbit-on-Rodent HRP Polymer (Biocare Medical) for 30 minutes at room temperature. Slides were washed and incubated with DAB (Betazoid DAB Chromagen kit, Biocare Medical), washed, and counterstained with hematoxylin. Stained slides were scanned with a Leica Aperio AT2 slide scanning microscope and analyzed with QuPath software (Bankhead et al., 2017). After blinding filenames, 4 equal-sized, randomly selected, independent regions of tissue were annotated for number of nuclei and number of apoptotic events. The percentage of apoptotic events for each animal was calculated from the total number of apoptotic hepatocytes and total number of nuclei from four representative 400x fields.

Micronucleus assay—Supplies for collecting mouse livers at MIT and shipping to Litron for flow cytometric hepatocyte micronucleus (MNHEP) scoring were from Prototype In Vivo MicroFlow[®] BASIC ML Kits, Litron Laboratories and included Liver Preservation Buffer Solution, 2 ml vials and ExaktPak shipping containers with ice packs. Reagents and supplies used at Litron for preparing livers for MNHEP scoring were from Prototype In Vivo MicroFlow[®] PLUS ML Kits, Litron Laboratories and included Liver Rinse, EGTA Solution, Collagenase Solution, Incomplete Lysis Solution 1, Incomplete Lysis Solution 2, anti-Ki67-eFluor[®] 660, Liver Nucleic Acid Dye (contains SYTOX[®] Green), and RNase Solution.

Mice (n = 4 males, 4 females of each group) were euthanized 48 hours after the second NDMA injection and livers were collected into 1 mL ice-cold Liver Preservation Buffer, packed on ice, and shipped overnight to Litron Laboratories. Upon receipt at Litron, each liver was removed from the Liver Preservation Buffer, patted dry, placed into a separate flask containing 10 mL of Liver Rinse Solution, and processed as described previously (Avlasevich et al., 2018). Samples were analyzed with a FACSCanto™ II flow cytometer equipped with 488 and 633 nM excitation (BD Biosciences, San Jose, CA).

Instrumentation settings and data acquisition/analysis were controlled with FACSDiva™ software v6.1.3 (BD Biosciences). SYTOX Green-associated fluorescence emissions were collected in the FITC channel (530/30 band-pass filter), and anti-Ki67-eFluo^R 660-associated fluorescence emissions were collected in the APC channel (660/20 band-pass filter). The flow cytometry gating strategy for MNHEP scoring required events to fall within each of three regions and one histogram marker before they were scored as nuclei or micronuclei. The incidence of flow cytometry-scored MNHEP is expressed as frequency percent (no. micronuclei/no. nuclei x 100) of 20,000 SYTOX Green positive nuclei per specimen. Simultaneous with micronucleus assessments, an experimental index of hepatocyte proliferation was collected based on gating for Ki67-positive nuclei.

MNHEP microscopy was performed by adding SYTOX Green-stained cells to acridine orange-coated slides, then imaged on an Olympus BH-2 microscope with a 40x objective as previously described (Avlasevich et al., 2018).

Tumor analysis—Gross surface lesions on the entire liver were recorded at necropsy. Distinct macroscopic tumors were enumerated; multifocal to coalescing tumorous regions were counted as one. WT saline n = 12 males, 12 females; WT NDMA n = 12 males, 12 females; *Aag*^{-/-} saline n = 12 males, 12 females; *Aag*^{-/-} NDMA n = 11 males, 11 females; *AagTg* saline n = 12 males, 12 females; *AagTg* NDMA n = 12 males, 12 females.

QUANTIFICATION AND STATISTICAL ANALYSES

Statistical analyses were performed using the GraphPad Prism software. Tumor multiplicity, RaDR foci, *gpt* mutant fractions, caspase staining, and histopathology scores were compared by Mann-Whitney *U*-test. Phosphoproteome, micronucleus, γ H2AX, and Ki67 analyses were compared by unpaired Student's *t*-test. A *P* value was considered significant if less than 0.05.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This work was supported by the National Institute of Environmental Health Sciences (NIEHS) Superfund Basic Research Program, National Institutes of Health (NIH), P42-ES027707; NIEHS Core Center Grant, NIH, P30-ES002109; NIEHS Toxicology Training Grant, NIH T32-ES007020; NIH Grant R01-CA080024; NIEHS Small Business Innovation Research Grant, NIH R44-ES026464; and NIH Biomedical Technology Research Resource Grant 5-P41EB015871-32, and the Center for Advanced Imaging at Harvard University.

We thank Caroline Atkinson and Joanna Richards in the MIT Division of Comparative Medicine for H&E and cleaved caspase-3 staining and Kathleen Cormier in the MIT Koch Institute Histology Core for Aperio slide scanning of caspase-stained slides. We appreciate the assistance of Aimee Moise in necropsies and RaDR imaging and Judy Yau in *gpt* analysis. We thank Jeff Dixon for creating the Template Switching and Fork Breakdown diagrams in Figure S7.

References

- AISSI-BEN MOUSSA S, MOUSSA A, LOVECCHIO T, KOURDA N, NAJJAR T, BEN JILANI S, EL GAAIED A, PORCHET N, MANAI M & BUISINE MP 2009. Identification and characterization of a novel MLH1 genomic rearrangement as the cause of HNPCC in a Tunisian family: evidence for a homologous Alu-mediated recombination. *Fam Cancer*, 8, 119–26. [PubMed: 18792805]
- AIT SAADA A, LAMBERT SAE & CARR AM 2018. Preserving replication fork integrity and competence via the homologous recombination pathway. *DNA Repair (Amst)*, 71, 135–147. [PubMed: 30220600]
- ALHUMAYDHI FA, DE OLD, BORDIN DL, ALJOHANI ASM, LLOYD CB, MCNICHOLAS MD, MILANO L, CHARLIER CF, VILLELA I, HENRIQUES JAP, PLANT KE, ELLIOTT RM & MEIRA LB 2020. Alkyladenine DNA glycosylase deficiency uncouples alkylation-induced strand break generation from PARP-1 activation and glycolysis inhibition. *Sci Rep*, 10, 2209. [PubMed: 32042007]
- ALLOCCA M, CORRIGAN JJ, FAKE KR, CALVO JA & SAMSON LD 2017. PARP inhibitors protect against sex- and AAG-dependent alkylation-induced neural degeneration. *Oncotarget*, 8, 68707–68720. [PubMed: 28978150]
- ALLOCCA M, CORRIGAN JJ, MAZUMDER A, FAKE KR & SAMSON LD 2019. Inflammation, necrosis, and the kinase RIP3 are key mediators of AAG-dependent alkylation-induced retinal degeneration. *Sci Signal*, 12.
- ANWAR SL, WULANINGSIH W & LEHMANN U 2017. Transposable Elements in Human Cancer: Causes and Consequences of Deregulation. *Int J Mol Sci*, 18.
- AVLASEVICH SL, KHANAL S, SINGH P, TOROUS DK, BEMIS JC & DERTINGER SD 2018. Flow cytometric method for scoring rat liver micronuclei with simultaneous assessments of hepatocyte proliferation. *Environ Mol Mutagen*, 59, 176–187. [PubMed: 29356121]
- BANKHEAD P, LOUGHREY MB, FERNANDEZ JA, DOMBROWSKI Y, MCART DG, DUNNE PD, MCQUAID S, GRAY RT, MURRAY LJ, COLEMAN HG, JAMES JA, SALTO-TELLEZ M & HAMILTON PW 2017. QuPath: Open source software for digital pathology image analysis. *Sci Rep*, 7, 16878. [PubMed: 29203879]
- BARITAUD M, CABON L, DELAVALLEE L, GALAN-MALO P, GILLES ME, BRUNELLE-NAVAS MN & SUSIN SA 2012. AIF-mediated caspase-independent necroptosis requires ATM and DNA-PK-induced histone H2AX Ser139 phosphorylation. *Cell Death Dis*, 3, e390. [PubMed: 22972376]
- BARNES JM & MAGEE PN 1954. Some toxic properties of dimethylnitrosamine. *Br J Ind Med*, 11, 167–74. [PubMed: 13182155]
- BECKTA JM, DEVER SM, GNAWALI N, KHALIL A, SULE A, GOLDING SE, ROSENBERG E, NARAYANAN A, KEHN-HALL K, XU B, POVIRK LF & VALERIE K 2015. Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced homologous recombination, and a compensatory increase in non-homologous end joining. *Oncotarget*, 6, 27674–87. [PubMed: 26320175]
- BEKKER-JENSEN S & MAILAND N 2010. Assembly and function of DNA double-strand break repair foci in mammalian cells. *DNA Repair (Amst)*, 9, 1219–28. [PubMed: 21035408]
- BERANEK DT 1990. Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. *Mutat Res*, 231, 11–30. [PubMed: 2195323]
- BERG S, KUTRA D, KROEGER T, STRAEHLE CN, KAUSLER BX, HAUBOLD C, SCHIEGG M, ALES J, BEIER T, RUDY M, EREN K, CERVANTES JI, XU B, BEUTTENMUELLER F, WOLNY A, ZHANG C, KOETHE U, HAMPRECHT FA & KRESHUK A 2019. *ilastik*:

- interactive machine learning for (bio)image analysis. *Nat Methods*, 16, 1226–1232. [PubMed: 31570887]
- BISHOP AJ & SCHIESTL RH 2001. Homologous recombination as a mechanism of carcinogenesis. *Biochim Biophys Acta*, 1471, M109–21. [PubMed: 11250067]
- BRYANT HE, PETERMANN E, SCHULTZ N, JEMTH AS, LOSEVA O, ISSAEVA N, JOHANSSON F, FERNANDEZ S, MCGLYNN P & HELLEDAY T 2009. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. *EMBO J*, 28, 2601–15. [PubMed: 19629035]
- CALVO JA, ALLOCCA M, FAKE KR, MUTHUPALANI S, CORRIGAN JJ, BRONSON RT & SAMSON LD 2016. Parp1 protects against Aag-dependent alkylation-induced nephrotoxicity in a sex-dependent manner. *Oncotarget*, 7, 44950–44965. [PubMed: 27391435]
- CALVO JA, MEIRA LB, LEE CY, MOROSKI-ERKUL CA, ABOLHASSANI N, TAGHIZADEH K, EICHINGER LW, MUTHUPALANI S, NORDSTRAND LM, KLUNGLAND A & SAMSON LD 2012. DNA repair is indispensable for survival after acute inflammation. *J Clin Invest*, 122, 2680–9. [PubMed: 22684101]
- CALVO JA, MOROSKI-ERKUL CA, LAKE A, EICHINGER LW, SHAH D, JHUN I, LIMSIRICHA P, BRONSON RT, CHRISTIANI DC, MEIRA LB & SAMSON LD 2013. Aag DNA glycosylase promotes alkylation-induced tissue damage mediated by Parp1. *PLoS Genet*, 9, e1003413. [PubMed: 23593019]
- CHAIM IA, NAGEL ZD, JORDAN JJ, MAZZUCATO P, NGO LP & SAMSON LD 2017. In vivo measurements of interindividual differences in DNA glycosylases and APE1 activities. *Proc Natl Acad Sci U S A*, 114, E10379–E10388. [PubMed: 29122935]
- CHANOUX RA, YIN B, URTISHAK KA, ASARE A, BASSING CH & BROWN EJ 2009. ATR and H2AX cooperate in maintaining genome stability under replication stress. *J Biol Chem*, 284, 5994–6003. [PubMed: 19049966]
- CHARYCH DH, COYNE M, YABANNAVAR A, NARBERES J, CHOW S, WALLROTH M, SHAFER C & WALTER AO 2008. Inhibition of Cdc7/Dbf4 kinase activity affects specific phosphorylation sites on MCM2 in cancer cells. *J Cell Biochem*, 104, 1075–86. [PubMed: 18286467]
- CHAWANTHAYATHAM S, VALENTINE CC 3RD, FEDELES BI, FOX EJ, LOEB LA, LEVINE SS, SLOCUM SL, WOGAN GN, CROY RG & ESSIGMANN JM 2017. Mutational spectra of aflatoxin B1 in vivo establish biomarkers of exposure for human hepatocellular carcinoma. *Proc Natl Acad Sci U S A*, 114, E3101–E3109. [PubMed: 28351974]
- COQUERELLE T, DOSCH J & KAINA B 1995. Overexpression of N-methylpurine-DNA glycosylase in Chinese hamster ovary cells renders them more sensitive to the production of chromosomal aberrations by methylating agents--a case of imbalanced DNA repair. *Mutat Res*, 336, 9–17. [PubMed: 7528899]
- CORTEZ D, GLICK G & ELLEDGE SJ 2004. Minichromosome maintenance proteins are direct targets of the ATM and ATR checkpoint kinases. *Proc Natl Acad Sci U S A*, 101, 10078–83. [PubMed: 15210935]
- CROSBIE PA, WATSON AJ, AGIUS R, BARBER PV, MARGISON GP & POVEY AC 2012. Elevated N3-methylpurine-DNA glycosylase DNA repair activity is associated with lung cancer. *Mutat Res*, 732, 43–6. [PubMed: 22266085]
- CRUET-HENNEQUART S, VILLALAN S, KACZMARCZYK A, O'MEARA E, SOKOL AM & CARTY MP 2009. Characterization of the effects of cisplatin and carboplatin on cell cycle progression and DNA damage response activation in DNA polymerase eta-deficient human cells. *Cell Cycle*, 8, 3039–50. [PubMed: 19713747]
- CUI F, SIROTIN MV & ZHURKIN VB 2011. Impact of Alu repeats on the evolution of human p53 binding sites. *Biol Direct*, 6, 2. [PubMed: 21208455]
- DANIEL JA, PELLEGRINI M, LEE JH, PAULL TT, FEIGENBAUM L & NUSSENZWEIG A 2008. Multiple autophosphorylation sites are dispensable for murine ATM activation in vivo. *J Cell Biol*, 183, 777–83. [PubMed: 19047460]

- DASS SB, BUCCI TJ, HEFLICH RH & CASCIANO DA 1999. Evaluation of the transgenic p53+/- mouse for detecting genotoxic liver carcinogens in a short-term bioassay. *Cancer Lett*, 143, 81–5. [PubMed: 10465341]
- DASS SB, HAMMONS GJ, BUCCI TJ, HEFLICH RH & CASCIANO DA 1998. Susceptibility of C57BL/6 mice to tumorigenicity induced by dimethylnitrosamine and 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine in the neonatal bioassay. *Cancer Lett*, 124, 105–10. [PubMed: 9500198]
- DITTMANN A, KENNEDY NJ, SOLTERO NL, MORSHED N, MANA MD, YILMAZ OH, DAVIS RJ & WHITE FM 2019. High-fat diet in a mouse insulin-resistant model induces widespread rewiring of the phosphotyrosine signaling network. *Mol Syst Biol*, 15, e8849. [PubMed: 31464373]
- DOUBLIE S & ELLENBERGER T 1998. The mechanism of action of T7 DNA polymerase. *Curr Opin Struct Biol*, 8, 704–12. [PubMed: 9914251]
- EBRAHIMKHANI MR, DANESHMAND A, MAZUMDER A, ALLOCCA M, CALVO JA, ABOLHASSANI N, JHUN I, MUTHUPALANI S, AYATA C & SAMSON LD 2014. Aag-initiated base excision repair promotes ischemia reperfusion injury in liver, brain, and kidney. *Proc Natl Acad Sci U S A*, 111, E4878–86. [PubMed: 25349415]
- ENGELWARD BP, ALLAN JM, DRESLIN AJ, KELLY JD, WU MM, GOLD B & SAMSON LD 1998. A chemical and genetic approach together define the biological consequences of 3-methyladenine lesions in the mammalian genome. *J Biol Chem*, 273, 5412–8. [PubMed: 9479003]
- ENGELWARD BP, DRESLIN A, CHRISTENSEN J, HUSZAR D, KURAHARA C & SAMSON L 1996. Repair-deficient 3-methyladenine DNA glycosylase homozygous mutant mouse cells have increased sensitivity to alkylation-induced chromosome damage and cell killing. *EMBO J*, 15, 945–52. [PubMed: 8631315]
- ENGELWARD BP, WEEDA G, WYATT MD, BROEKHOF JL, DE WIT J, DONKER I, ALLAN JM, GOLD B, HOEIJMAKERS JH & SAMSON LD 1997. Base excision repair deficient mice lacking the Aag alkyladenine DNA glycosylase. *Proc Natl Acad Sci U S A*, 94, 13087–92. [PubMed: 9371804]
- ENSMINGER M, ILOFF L, EBEL C, NIKOLOVA T, KAINA B & LBRICH M 2014. DNA breaks and chromosomal aberrations arise when replication meets base excision repair. *J Cell Biol*, 206, 29–43. [PubMed: 24982429]
- EWALD B, SAMPATH D & PLUNKETT W 2007. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. *Mol Cancer Ther*, 6, 1239–48. [PubMed: 17406032]
- FAHRER J, FRISCH J, NAGEL G, KRAUS A, DORSAM B, THOMAS AD, REISSIG S, WAISMAN A & KAINA B 2015. DNA repair by MGMT, but not AAG, causes a threshold in alkylation-induced colorectal carcinogenesis. *Carcinogenesis*, 36, 1235–44. [PubMed: 26243310]
- FOSTER SS, DE S, JOHNSON LK, PETRINI JH & STRACKER TH 2012. Cell cycle- and DNA repair pathway-specific effects of apoptosis on tumor suppression. *Proc Natl Acad Sci U S A*, 109, 9953–8. [PubMed: 22670056]
- GANINI D, LEINISCH F, KUMAR A, JIANG J, TOKAR EJ, MALONE CC, PETROVICH RM & MASON RP 2017. Fluorescent proteins such as eGFP lead to catalytic oxidative stress in cells. *Redox Biol*, 12, 462–468. [PubMed: 28334681]
- GATEI M, JAKOB B, CHEN P, KIJAS AW, BECHEREL OJ, GUEVEN N, BIRRELL G, LEE JH, PAULL TT, LERENTHAL Y, FAZRY S, TAUCHER-SCHOLZ G, KALB R, SCHINDLER D, WALTES R, DORK T & LAVIN MF 2011. ATM protein-dependent phosphorylation of Rad50 protein regulates DNA repair and cell cycle control. *J Biol Chem*, 286, 31542–56. [PubMed: 21757780]
- GATES KS, NOONER T & DUTTA S 2004. Biologically relevant chemical reactions of N7-alkylguanine residues in DNA. *Chem Res Toxicol*, 17, 839–56. [PubMed: 15257608]
- GEORGE J, TSUCHISHIMA M & TSUTSUMI M 2019. Molecular mechanisms in the pathogenesis of N-nitrosodimethylamine induced hepatic fibrosis. *Cell Death Dis*, 10, 18. [PubMed: 30622238]
- GUPTA PK, SAHOTA A, BOYADJIEV SA, BYE S, SHAO C, O'NEILL JP, HUNTER TC, ALBERTINI RJ, STAMBROOK PJ & TISCHFIELD JA 1997. High frequency in vivo loss of

- heterozygosity is primarily a consequence of mitotic recombination. *Cancer Res*, 57, 1188–93. [PubMed: 9067291]
- HAGGERTY HG & HOLSAPPLE MP 1990. Role of metabolism in dimethylnitrosamine-induced immunosuppression: a review. *Toxicology*, 63, 1–23. [PubMed: 2200161]
- HAIGIS KM & DOVE WF 2003. A Robertsonian translocation suppresses a somatic recombination pathway to loss of heterozygosity. *Nat Genet*, 33, 33–9. [PubMed: 12447373]
- HAINCE JF, MCDONALD D, RODRIGUE A, DERY U, MASSON JY, HENDZEL MJ & POIRIER GG 2008. PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. *J Biol Chem*, 283, 1197–208. [PubMed: 18025084]
- HALL J, BRESIL H, DONATO F, WILD CP, LOKTIONOVA NA, KAZANOVA OI, KOMYAKOV IP, LEMEKHOV VG, LIKHACHEV AJ & MONTESANO R 1993. Alkylation and oxidative-DNA damage repair activity in blood leukocytes of smokers and non-smokers. *Int J Cancer*, 54, 728–33. [PubMed: 8325702]
- HANADA K, BUDZOWSKA M, DAVIES SL, VAN DRUNEN E, ONIZAWA H, BEVERLOO HB, MAAS A, ESSERS J, HICKSON ID & KANAAR R 2007. The structure-specific endonuclease Mus81 contributes to replication restart by generating double-strand DNA breaks. *Nat Struct Mol Biol*, 14, 1096–104. [PubMed: 17934473]
- HANADA K, BUDZOWSKA M, MODESTI M, MAAS A, WYMAN C, ESSERS J & KANAAR R 2006. The structure-specific endonuclease Mus81-Eme1 promotes conversion of interstrand DNA crosslinks into double-strands breaks. *EMBO J*, 25, 4921–32. [PubMed: 17036055]
- HARACSKA L, UNK I, JOHNSON RE, JOHANSSON E, BURGERS PM, PRAKASH S & PRAKASH L 2001. Roles of yeast DNA polymerases delta and zeta and of Rev1 in the bypass of abasic sites. *Genes Dev*, 15, 945–54. [PubMed: 11316789]
- HASSAN MM, BOTRUS G, ABDEL-WAHAB R, WOLFF RA, LI D, TWEARDY D, PHAN AT, HAWK E, JAVLE M, LEE JS, TORRES HA, RASHID A, LENZI R, HASSABO HM, ABAZA Y, SHALABY AS, LACIN S, MORRIS J, PATT YZ, AMOS CI, KHADERI SA, GOSS JA, JALAL PK & KASEB AO 2017. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. *Clin Gastroenterol Hepatol*, 15, 1791–1799. [PubMed: 28579181]
- HE M, CROY RG, ESSIGMANN JM & SWAGER TM 2019. Chemiresistive Carbon Nanotube Sensors for N-Nitrosodialkylamines. *ACS Sens*.
- HEATH DFM, AR 1961. Preparation of 14C-labelled dialkyl nitrosamines and an improved preparation of N-methyl-N-t-butylamine. *J Chem Soc*, 4226–4229.
- HENDRICKS CA, RAZLOG M, MATSUGUCHI T, GOYAL A, BROCK AL & ENGELWARD BP 2002. The *S. cerevisiae* Mag1 3-methyladenine DNA glycosylase modulates susceptibility to homologous recombination. *DNA Repair (Amst)*, 1, 645–59. [PubMed: 12509287]
- HUANG X, OKAFUJI M, TRAGANOS F, LUTHER E, HOLDEN E & DARZYNKIEWICZ Z 2004. Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin. *Cytometry A*, 58, 99–110. [PubMed: 15057963]
- IARC 2010. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Ingested Nitrate and Nitrite, and Cyanobacterial Peptide Toxins.
- IARC 2015. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Red Meat and Processed Meat.
- IBEANU G, HARTENSTEIN B, DUNN WC, CHANG LY, HOFMANN E, COQUERELLE T, MITRA S & KAINA B 1992. Overexpression of human DNA repair protein N-methylpurine-DNA glycosylase results in the increased removal of N-methylpurines in DNA without a concomitant increase in resistance to alkylating agents in Chinese hamster ovary cells. *Carcinogenesis*, 13, 1989–95. [PubMed: 1423866]
- IYER SS, PULSKENS WP, SADLER JJ, BUTTER LM, TESKE GJ, ULLAND TK, EISENBARTH SC, FLORQUIN S, FLAVELL RA, LEEMANS JC & SUTTERWALA FS 2009. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. *Proc Natl Acad Sci U S A*, 106, 20388–93. [PubMed: 19918053]

- JOHNSON RE, YU SL, PRAKASH S & PRAKASH L 2007. A role for yeast and human translesion synthesis DNA polymerases in promoting replication through 3-methyl adenine. *Mol Cell Biol*, 27, 7198–205. [PubMed: 17698580]
- KAINA B, FRITZ G & COQUERELLE T 1993. Contribution of O6-alkylguanine and N-alkylpurines to the formation of sister chromatid exchanges, chromosomal aberrations, and gene mutations: new insights gained from studies of genetically engineered mammalian cell lines. *Environ Mol Mutagen*, 22, 283–92. [PubMed: 8223512]
- KARABATSOS GJT, RA 1964. Structural studies by Nuclear Magnetic Resonance. IX. Configuration of N-Nitrosamines. *J Am Chem Soc*, 86, 4373–4378.
- KATSUBE T, MORI M, TSUJI H, SHIOMI T, WANG B, LIU Q, NENOI M & ONODA M 2014. Most hydrogen peroxide-induced histone H2AX phosphorylation is mediated by ATR and is not dependent on DNA double-strand breaks. *J Biochem*, 156, 85–95. [PubMed: 24682951]
- KIMOTO W 1980. Role of strong ion exchange resins in nitrosamine formation in water. *Water Res*.
- KIRALY O, GONG G, ROYTMAN MD, YAMADA Y, SAMSON LD & ENGELWARD BP 2014. DNA glycosylase activity and cell proliferation are key factors in modulating homologous recombination in vivo. *Carcinogenesis*, 35, 2495–502. [PubMed: 25155011]
- KISBY GE, OLIVAS A, PARK T, CHURCHWELL M, DOERGE D, SAMSON LD, GERSON SL & TURKER MS 2009. DNA repair modulates the vulnerability of the developing brain to alkylating agents. *DNA Repair (Amst)*, 8, 400–12. [PubMed: 19162564]
- KLAPACZ J, LINGARAJU GM, GUO HH, SHAH D, MOAR-SHOSHANI A, LOEB LA & SAMSON LD 2010. Frameshift mutagenesis and microsatellite instability induced by human alkyladenine DNA glycosylase. *Mol Cell*, 37, 843–53. [PubMed: 20347426]
- KOLOMIETZ E, MEYN MS, PANDITA A & SQUIRE JA 2002. The role of Alu repeat clusters as mediators of recurrent chromosomal aberrations in tumors. *Genes Chromosomes Cancer*, 35, 97–112. [PubMed: 12203773]
- KROKAN HE & BJORAS M 2013. Base excision repair. *Cold Spring Harb Perspect Biol*, 5, a012583. [PubMed: 23545420]
- LAMBERT IB, SINGER TM, BOUCHER SE & DOUGLAS GR 2005. Detailed review of transgenic rodent mutation assays. *Mutat Res*, 590, 1–280. [PubMed: 16081315]
- LAMBERT S, MIZUNO K, BLAISONNEAU J, MARTINEAU S, CHANET R, FREON K, MURRAY JM, CARR AM & BALDACCI G 2010. Homologous recombination restarts blocked replication forks at the expense of genome rearrangements by template exchange. *Mol Cell*, 39, 346–59. [PubMed: 20705238]
- LANGE SS, TAKATA K & WOOD RD 2011. DNA polymerases and cancer. *Nat Rev Cancer*, 11, 96–110. [PubMed: 21258395]
- LARSON K, SAHM J, SHENKAR R & STRAUSS B 1985. Methylation-induced blocks to in vitro DNA replication. *Mutat Res*, 150, 77–84. [PubMed: 4000169]
- LEE VM, KEEFER LK & ARCHER MC 1996. An evaluation of the roles of metabolic denitrosation and alpha-hydroxylation in the hepatotoxicity of N-Nitrosodimethylamine. *Chem Res Toxicol*, 9, 1319–24. [PubMed: 8951235]
- LEITNER-DAGAN Y, SEVILYA Z, PINCHEV M, KRAMER R, ELINGER D, ROISMAN LC, RENNERT HS, SCHECHTMAN E, FREEDMAN L, RENNERT G, LIVNEH Z & PAZ-ELIZUR T 2012. N-methylpurine DNA glycosylase and OGG1 DNA repair activities: opposite associations with lung cancer risk. *J Natl Cancer Inst*, 104, 1765–9. [PubMed: 23104324]
- LI M & YU X 2013. Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. *Cancer Cell*, 23, 693–704. [PubMed: 23680151]
- LI Q, HAO Q, CAO W, LI J, WU K, ELSHIMALI Y, ZHU D, CHEN QH, CHEN G, POLLACK JR, VADGAMA J & WU Y 2019. PP2Cdelta inhibits p300-mediated p53 acetylation via ATM/BRCA1 pathway to impede DNA damage response in breast cancer. *Sci Adv*, 5, eaaw8417. [PubMed: 31663018]
- LIKHITE VS, CASS EI, ANDERSON SD, YATES JR & NARDULLI AM 2004. Interaction of estrogen receptor alpha with 3-methyladenine DNA glycosylase modulates transcription and DNA repair. *J Biol Chem*, 279, 16875–82. [PubMed: 14761960]

- LOKTIONOV A, HOLLSTEIN M, MARTEL N, GALENDO D, CABRAL JR, TOMATIS L & YAMASAKI H 1990. Tissue-specific activating mutations of Ha- and Ki-ras oncogenes in skin, lung, and liver tumors induced in mice following transplacental exposure to DMBA. *Mol Carcinog*, 3, 134–40. [PubMed: 1973614]
- LOWE SW & LIN AW 2000. Apoptosis in cancer. *Carcinogenesis*, 21, 485–95. [PubMed: 10688869]
- MAKRIDAKIS NM & REICHARDT JK 2012. Translesion DNA polymerases and cancer. *Front Genet*, 3, 174. [PubMed: 22973298]
- MARGULIES CM, CHAIM IA, MAZUMDER A, CRISCIONE J & SAMSON LD 2017. Alkylation induced cerebellar degeneration dependent on Aag and Parp1 does not occur via previously established cell death mechanisms. *PLoS One*, 12, e0184619. [PubMed: 28886188]
- MARIANS KJ 2018. Lesion Bypass and the Reactivation of Stalled Replication Forks. *Annu Rev Biochem*, 87, 217–238. [PubMed: 29298091]
- MATSUOKA S, BALLIF BA, SMOGORZEWSKA A, MCDONALD ER 3RD, HUOV KE, LUO J, BAKALARSKI CE, ZHAO Z, SOLIMINI N, LERENTHAL Y, SHILOH Y, GYGI SP & ELLEDGE SJ 2007. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. *Science*, 316, 1160–6. [PubMed: 17525332]
- MAZOUZI A, STUKALOV A, MULLER AC, CHEN D, WIEDNER M, PROCHAZKOVA J, CHIANG SC, SCHUSTER M, BREITWIESER FP, PICHLMAIR A, EL-KHAMISY SF, BOCK C, KRALOVICS R, COLINGE J, BENNETT KL & LOIZOU JI 2016. A Comprehensive Analysis of the Dynamic Response to Aphidicolin-Mediated Replication Stress Uncovers Targets for ATM and ATMIN. *Cell Rep*, 15, 893–908. [PubMed: 27149854]
- MEIRA LB, BUGNI JM, GREEN SL, LEE CW, PANG B, BORENSHTEIN D, RICKMAN BH, ROGERS AB, MOROSKI-ERKUL CA, MCFALINE JL, SCHAUER DB, DEDON PC, FOX JG & SAMSON LD 2008. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. *J Clin Invest*, 118, 2516–25. [PubMed: 18521188]
- MEIRA LB, MOROSKI-ERKUL CA, GREEN SL, CALVO JA, BRONSON RT, SHAH D & SAMSON LD 2009. Aag-initiated base excision repair drives alkylation-induced retinal degeneration in mice. *Proc Natl Acad Sci U S A*, 106, 888–93. [PubMed: 19139400]
- MIENTJES EJ, LUITEN-SCHUITE A, VAN DER WOLF E, BORSBOOM Y, BERGMANS A, BERENDS F, LOHMAN PH, BAAN RA & VAN DELFT JH 1998. DNA adducts, mutant frequencies, and mutation spectra in various organs of lambda lacZ mice exposed to ethylating agents. *Environ Mol Mutagen*, 31, 18–31. [PubMed: 9464312]
- MITCH WA & SEDLAK DL 2004. Characterization and fate of N-nitrosodimethylamine precursors in municipal wastewater treatment plants. *Environ Sci Technol*, 38, 1445–54. [PubMed: 15046346]
- MOEGLIN E, DESPLANCQ D, CONIC S, OULAD-ABDELGHANI M, STOESSEL A, CHIPER M, VIGNERON M, DIDIER P, TORA L & WEISS E 2019. Uniform Widespread Nuclear Phosphorylation of Histone H2AX Is an Indicator of Lethal DNA Replication Stress. *Cancers (Basel)*, 11.
- MONTI P, TRAVERSO I, CASOLARI L, MENICHINI P, INGA A, OTTAGGIO L, RUSSO D, IYER P, GOLD B & FRONZA G 2010. Mutagenicity of N3-methyladenine: a multi-translesion polymerase affair. *Mutat Res*, 683, 50–6. [PubMed: 19874831]
- NAGEL ZD, MARGULIES CM, CHAIM IA, MCREE SK, MAZZUCATO P, AHMAD A, ABO RP, BUTTY VL, FORGET AL & SAMSON LD 2014. Multiplexed DNA repair assays for multiple lesions and multiple doses via transcription inhibition and transcriptional mutagenesis. *Proc Natl Acad Sci U S A*, 111, E1823–32. [PubMed: 24757057]
- NAUGLER WE, SAKURAI T, KIM S, MAEDA S, KIM K, ELSHARKAWY AM & KARIN M 2007. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. *Science*, 317, 121–4. [PubMed: 17615358]
- NISHIKAWA A, FURUKAWA F, KASAHARA K, LEE IS, SUZUKI T, HAYASHI M, SOFUNI T & TAKAHASHI M 1997. Comparative study on organ-specificity of tumorigenicity, mutagenicity and cell proliferative activity induced by dimethylnitrosamine in Big Blue mice. *Cancer Lett*, 117, 143–7. [PubMed: 9377541]
- NOHMI T, KATOH M, SUZUKI H, MATSUI M, YAMADA M, WATANABE M, SUZUKI M, HORIYA N, UEDA O, SHIBUYA T, IKEDA H & SOFUNI T 1996. A new transgenic mouse

- mutagenesis test system using Spi- and 6-thioguanine selections. *Environ Mol Mutagen*, 28, 465–70. [PubMed: 8991079]
- NORBURY CJ & ZHIVOTOVSKY B 2004. DNA damage-induced apoptosis. *Oncogene*, 23, 2797–808. [PubMed: 15077143]
- OGIWARA H, KOHNO T, NAKANISHI H, NAGAYAMA K, SATO M & YOKOTA J 2008. Unbalanced translocation, a major chromosome alteration causing loss of heterozygosity in human lung cancer. *Oncogene*, 27, 4788–97. [PubMed: 18408757]
- PAGES V, JOHNSON RE, PRAKASH L & PRAKASH S 2008. Mutational specificity and genetic control of replicative bypass of an abasic site in yeast. *Proc Natl Acad Sci U S A*, 105, 1170–5. [PubMed: 18202176]
- PAL J, BERTHEAU R, BUON L, QAZI A, BATCHU RB, BANDYOPADHYAY S, ALI-FEHMI R, BEER DG, WEAVER DW, SHMOOKLER REIS RJ, GOYAL RK, HUANG Q, MUNSHI NC & SHAMMAS MA 2011. Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome. *Oncogene*, 30, 3585–98. [PubMed: 21423218]
- PARR MK & JOSEPH JF 2019. NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N-nitrosamines. *J Pharm Biomed Anal*, 164, 536–549. [PubMed: 30458387]
- PARRISH MC, CHAIM IA, NAGEL ZD, TANNENBAUM SR, SAMSON LD & ENGELWARD BP 2018. Nitric oxide induced S-nitrosation causes base excision repair imbalance. *DNA Repair (Amst)*, 68, 25–33. [PubMed: 29929044]
- PEGG AE & HUI G 1978. Formation and subsequent removal of O6-methylguanine from deoxyribonucleic acid in rat liver and kidney after small doses of dimethylnitrosamine. *Biochem J*, 173, 739–48. [PubMed: 708371]
- PELLEGRINI M, CELESTE A, DIFILIPPANTONIO S, GUO R, WANG W, FEIGENBAUM L & NUSSENZWEIG A 2006. Autophosphorylation at serine 1987 is dispensable for murine Atm activation in vivo. *Nature*, 443, 222–5. [PubMed: 16906133]
- PEREZ-RIVEROL Y, CSORDAS A, BAI J, BERNAL-LLINARES M, HEWAPATHIRANA S, KUNDU DJ, INUGANTI A, GRISS J, MAYER G, EISENACHER M, PEREZ E, USZKOREIT J, PFEUFFER J, SACHSENBERG T, YILMAZ S, TIWARY S, COX J, AUDAIN E, WALZER M, JARNUCZAK AF, TERNENT T, BRAZMA A & VIZCAINO JA 2019. The PRIDE database and related tools and resources in 2019: improving support for quantification data. *Nucleic Acids Res*, 47, D442–D450. [PubMed: 30395289]
- PETO R, GRAY R, BRANTOM P & GRASSO P 1991. Dose and time relationships for tumor induction in the liver and esophagus of 4080 inbred rats by chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine. *Cancer Res*, 51, 6452–69. [PubMed: 1933907]
- PIAZZA A, WRIGHT WD & HEYER WD 2017. Multi-invasions Are Recombination Byproducts that Induce Chromosomal Rearrangements. *Cell*, 170, 760–773 e15. [PubMed: 28781165]
- PLOSKY BS, FRANK EG, BERRY DA, VENNALL GP, MCDONALD JP & WOODGATE R 2008. Eukaryotic Y-family polymerases bypass a 3-methyl-2'-deoxyadenosine analog in vitro and methyl methanesulfonate-induced DNA damage in vivo. *Nucleic Acids Res*, 36, 2152–62. [PubMed: 18281311]
- POTTEGARD A, KRISTENSEN KB, ERNST MT, JOHANSEN NB, QUARTAROLO P & HALLAS J 2018. Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study. *BMJ*, 362, k3851. [PubMed: 30209057]
- RAO KV & VESSELINOVITCH SD 1973. Age- and sex-associated diethylnitrosamine dealkylation activity of the mouse liver and hepatocarcinogenesis. *Cancer Res*, 33, 1625–7. [PubMed: 4352793]
- RICHARDSON SD 2003. Disinfection by-products and other emerging contaminants in drinking water. *Trends in Analytical Chemistry*.
- ROBERTSON AB, KLUNGLAND A, ROGNES T & LEIROS I 2009. DNA repair in mammalian cells: Base excision repair: the long and short of it. *Cell Mol Life Sci*, 66, 981–93. [PubMed: 19153658]

- ROOS WP & KAINA B 2013. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. *Cancer Lett*, 332, 237–48. [PubMed: 22261329]
- SACHET M, LIANG YY & OEHLER R 2017. The immune response to secondary necrotic cells. *Apoptosis*, 22, 1189–1204. [PubMed: 28861714]
- SAUGAR I, VAZQUEZ MV, GALLO-FERNANDEZ M, ORTIZ-BAZAN MA, SEGURADO M, CALZADA A & TERCERO JA 2013. Temporal regulation of the Mus81-Mms4 endonuclease ensures cell survival under conditions of DNA damage. *Nucleic Acids Res*, 41, 8943–58. [PubMed: 23901010]
- SCHERF-CLAVEL O, KINZIG M, BESA A, SCHREIBER A, BIDMON C, ABDEL-TAWAB M, WOHLFART J, SORGEL F & HOLZGRABE U 2019. The contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities. *J Pharm Biomed Anal*, 172, 278–284. [PubMed: 31078064]
- SCHMEZER P, ECKERT C & LIEGIBEL UM 1994. Tissue-specific induction of mutations by streptozotocin in vivo. *Mutat Res*, 307, 495–9. [PubMed: 7514723]
- SCULLY R & XIE A 2013. Double strand break repair functions of histone H2AX. *Mutat Res*, 750, 5–14. [PubMed: 23916969]
- SEDLAK DL, DEEB RA, HAWLEY EL, MITCH WA, DURBIN TD, MOWBRAY S & CARR S 2005. Sources and fate of nitrosodimethylamine and its precursors in municipal wastewater treatment plants. *Water Environ Res*, 77, 32–9. [PubMed: 15765933]
- SHAO C, DENG L, HENEGARIU O, LIANG L, RAIKWAR N, SAHOTA A, STAMBROOK PJ & TISCHFIELD JA 1999. Mitotic recombination produces the majority of recessive fibroblast variants in heterozygous mice. *Proc Natl Acad Sci U S A*, 96, 9230–5. [PubMed: 10430925]
- SNIDER TA, RICHARDSON A, STONER JA & DEEPA SS 2018. The Geropathology Grading Platform demonstrates that mice null for Cu/Zn-superoxide dismutase show accelerated biological aging. *Geroscience*, 40, 97–103. [PubMed: 29478190]
- SOBOL RW, KARTALOU M, ALMEIDA KH, JOYCE DF, ENGELWARD BP, HORTON JK, PRASAD R, SAMSON LD & WILSON SH 2003. Base excision repair intermediates induce p53-independent cytotoxic and genotoxic responses. *J Biol Chem*, 278, 39951–9. [PubMed: 12882965]
- SOHN OS, ISHIZAKI H, YANG CS & FIALA ES 1991. Metabolism of azoxymethane, methylazoxymethanol and N-nitrosodimethylamine by cytochrome P450IIE1. *Carcinogenesis*, 12, 127–31. [PubMed: 1988172]
- SORGEL F, KINZIG M, ABDEL-TAWAB M, BIDMON C, SCHREIBER A, ERMEL S, WOHLFART J, BESA A, SCHERF-CLAVEL O & HOLZGRABE U 2019. The contamination of valsartan and other sartans, part 1: New findings. *J Pharm Biomed Anal*, 172, 395–405. [PubMed: 31122801]
- SORIANO P 1999. Generalized lacZ expression with the ROSA26 Cre reporter strain. *Nat Genet*, 21, 70–1. [PubMed: 9916792]
- SOULIOTIS VL, VAN DELFT JH, STEENWINKEL MJ, BAAN RA & KYRTOPOULOS SA 1998. DNA adducts, mutant frequencies and mutation spectra in lambda lacZ transgenic mice treated with N-nitrosodimethylamine. *Carcinogenesis*, 19, 731–9. [PubMed: 9635857]
- STRAUSS B, SCUDIERO D & HENDERSON E 1975. The nature of the alkylation lesion in mammalian cells. *Basic Life Sci*, 5A, 13–24. [PubMed: 1103819]
- STROUT MP, MARCUCCI G, BLOOMFIELD CD & CALIGIURI MA 1998. The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia. *Proc Natl Acad Sci U S A*, 95, 2390–5. [PubMed: 9482895]
- STUCKI M, CLAPPERTON JA, MOHAMMAD D, YAFFE MB, SMERDON SJ & JACKSON SP 2005. MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. *Cell*, 123, 1213–26. [PubMed: 16377563]
- SUKUP-JACKSON MR, KIRALY O, KAY JE, NA L, ROWLAND EA, WINTHER KE, CHOW DN, KIMOTO T, MATSUGUCHI T, JONNALAGADDA VS, MAKLAKOVA VI, SINGH VR, WADDUWAGE DN, RAJAPAKSE J, SO PT, COLLIER LS & ENGELWARD BP 2014.

- Rosa26-GFP direct repeat (RaDR-GFP) mice reveal tissue- and age-dependence of homologous recombination in mammals in vivo. *PLoS Genet*, 10, e1004299. [PubMed: 24901438]
- SUZUKI T, ITOH T, HAYASHI M, NISHIKAWA Y, IKEZAKI S, FURUKAWA F, TAKAHASHI M & SOFUNI T 1996. Organ variation in the mutagenicity of dimethylnitrosamine in Big Blue mice. *Environ Mol Mutagen*, 28, 348–53. [PubMed: 8991063]
- SWENBERG JA, HOEL DG & MAGEE PN 1991. Mechanistic and statistical insight into the large carcinogenesis bioassays on N-nitrosodiethylamine and N-nitrosodimethylamine. *Cancer Res*, 51, 6409–14. [PubMed: 1933905]
- TAUS T, KOCHER T, PICHLER P, PASCHKE C, SCHMIDT A, HENRICH C & MECHTLER K 2011. Universal and confident phosphorylation site localization using phosphoRS. *J Proteome Res*, 10, 5354–62. [PubMed: 22073976]
- THOOLEN B, MARONPOT RR, HARADA T, NYSKA A, ROUSSEAU C, NOLTE T, MALARKEY DE, KAUFMANN W, KUTTLER K, DESCHL U, NAKAE D, GREGSON R, VINLOVE MP, BRIX AE, SINGH B, BELPOGGI F & WARD JM 2010. Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system. *Toxicol Pathol*, 38, 5S–81S. [PubMed: 21191096]
- TOLBA R, KRAUS T, LIEDTKE C, SCHWARZ M & WEISKIRCHEN R 2015. Diethylnitrosamine (DEN)-induced carcinogenic liver injury in mice. *Lab Anim*, 49, 59–69. [PubMed: 25835739]
- TSUTSUMI T, AKIYAMA H, DEMIZU Y, UCHIYAMA N, MASADA S, TSUJI G, ARAI R, ABE Y, HAKAMATSUKA T, IZUTSU KI, GODA Y & OKUDA H 2019. Analysis of an Impurity, N-Nitrosodimethylamine, in Valsartan Drug Substances and Associated Products Using GC-MS. *Biol Pharm Bull*, 42, 547–551. [PubMed: 30726781]
- VESSELINOVITCH SD 1969. The sex-dependent difference in the development of liver tumors in mice administered dimethylnitrosamine. *Cancer Res*, 29, 1024–7. [PubMed: 4305498]
- WADDUWAGE DN, KAY J, SINGH VR, KIRALY O, SUKUP-JACKSON MR, RAJAPAKSE J, ENGELWARD BP & SO PTC 2018. Automated fluorescence intensity and gradient analysis enables detection of rare fluorescent mutant cells deep within the tissue of RaDR mice. *Sci Rep*, 8, 12108. [PubMed: 30108260]
- WALLACE SS, MURPHY DL & SWEASY JB 2012. Base excision repair and cancer. *Cancer Lett*, 327, 73–89. [PubMed: 22252118]
- WANG B, MATSUOKA S, BALLIF BA, ZHANG D, SMOGORZEWSKA A, GYGI SP & ELLEDGE SJ 2007. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. *Science*, 316, 1194–8. [PubMed: 17525340]
- WANG X, SUZUKI T, ITOH T, HONMA M, NISHIKAWA A, FURUKAWA F, TAKAHASHI M, HAYASHI M, KATO T & SOFUNI T 1998. Specific mutational spectrum of dimethylnitrosamine in the lacI transgene of Big Blue C57BL/6 mice. *Mutagenesis*, 13, 625–30. [PubMed: 9862195]
- WARD IM & CHEN J 2001. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. *J Biol Chem*, 276, 47759–62. [PubMed: 11673449]
- WEGHORST CM, PEREIRA MA & KLAUNIG JE 1989. Strain differences in hepatic tumor promotion by phenobarbital in diethylnitrosamine- and dimethylnitrosamine-initiated infant male mice. *Carcinogenesis*, 10, 1409–12. [PubMed: 2752514]
- WESTMAN J, GRINSTEIN S & MARQUES PE 2019. Phagocytosis of Necrotic Debris at Sites of Injury and Inflammation. *Front Immunol*, 10, 3030. [PubMed: 31998312]
- WILLIS N & RHIND N 2009. Mus81, Rhp51(Rad51), and Rqh1 form an epistatic pathway required for the S-phase DNA damage checkpoint. *Mol Biol Cell*, 20, 819–33. [PubMed: 19037101]
- WIRTZ S, NAGEL G, ESHKIND L, NEURATH MF, SAMSON LD & KAINA B 2010. Both base excision repair and O6-methylguanine-DNA methyltransferase protect against methylation-induced colon carcinogenesis. *Carcinogenesis*, 31, 2111–7. [PubMed: 20732909]
- XU B, KIM S & KASTAN MB 2001. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. *Mol Cell Biol*, 21, 3445–50. [PubMed: 11313470]
- XU Y, HUANG S, LIU ZG & HAN J 2006. Poly(ADP-ribose) polymerase-1 signaling to mitochondria in necrotic cell death requires RIP1/TRAF2-mediated JNK1 activation. *J Biol Chem*, 281, 8788–95. [PubMed: 16446354]

- YANG Q, LIN W, LIU Z, ZHU J, HUANG N, CUI Z, HAN Z, PAN Q, GOEL A & SUN F 2018. RAP80 is an independent prognosis biomarker for the outcome of patients with esophageal squamous cell carcinoma. *Cell Death Dis*, 9, 146. [PubMed: 29396516]
- YEELES JT, POLI J, MARIANS KJ & PASERO P 2013. Rescuing stalled or damaged replication forks. *Cold Spring Harb Perspect Biol*, 5, a012815. [PubMed: 23637285]
- YOON JH, ROY CHOUDHURY J, PARK J, PRAKASH S & PRAKASH L 2017. Translesion synthesis DNA polymerases promote error-free replication through the minor-groove DNA adduct 3-deaza-3-methyladenine. *J Biol Chem*, 292, 18682–18688. [PubMed: 28939775]
- YU SW, WANG H, POITRAS MF, COOMBS C, BOWERS WJ, FEDEROFF HJ, POIRIER GG, DAWSON TM & DAWSON VL 2002. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. *Science*, 297, 259–63. [PubMed: 12114629]
- ZHANG W, EDWARDS A, FAN W, DEININGER P & ZHANG K 2011. Alu distribution and mutation types of cancer genes. *BMC Genomics*, 12, 157. [PubMed: 21429208]
- ZHANG Y, YUAN F, WU X, RECHKOBLIT O, TAYLOR JS, GEACINTOV NE & WANG Z 2000. Error-prone lesion bypass by human DNA polymerase eta. *Nucleic Acids Res*, 28, 4717–24. [PubMed: 11095682]
- ZHAO L, LIN H, CHEN S, CHEN S, CUI M, SHI D, WANG B, MA K & SHAO Z 2018. Hydrogen peroxide induces programmed necrosis in rat nucleus pulposus cells through the RIP1/RIP3-PARP-AIF pathway. *J Orthop Res*, 36, 1269–1282. [PubMed: 28960436]

Diversity and inclusion statement

We worked to ensure sex balance in the selection of non-human subjects. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in science. One or more of the authors of this paper self-identifies as a member of the LGBTQ+ community. The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work.




Figure 1. *Aag* expression levels modulate NDMA-induced point mutations, phosphoproteomic responses, and homologous recombination-driven sequence rearrangements.

A) At 10 weeks after exposure, point mutations induced by NDMA were detected in the liver. Mann-Whitney *U*-test, * $p < 0.05$, # $p < 0.0001$, $n = 10$ per group. B) NDMA treatment induces phosphorylation of proteins involved in DSB recognition (blue font), replication stress (red), and HR (green) 24h post-exposure. Volcano plot of phosphorylation sites quantified from ATM/ATR substrate motif specific (phospho-SQ/TQ) proteomic analysis in WT mouse livers treated with saline ($n = 2$) or NDMA ($n = 3$). \log_2 fold changes are relative to saline control. *P*-values were calculated based on two-tailed Student's *t*-test

and were corrected for multiple hypothesis testing based on Benjamini-Hochberg FDR correction. See also Table S1. C) The RaDR transgenic construct consists of a direct repeat of two EGFP expression cassettes, wherein the 5' cDNA has been truncated at the 5' end and the 3' cDNA has been truncated at the 3' end. See also Figure S7. D) Representative RaDR liver images from each group, 10 months post-exposure. Large image scale bar = 5 mm, inset scale bar = 1 mm. See also Figure S3. E) NDMA induces sequence rearrangement mutations detected 10 weeks post-exposure. WT saline n = 24; WT NDMA n = 22; *Aag*^{-/-} saline n = 22; *Aag*^{-/-} NDMA n = 24; *AagTg* saline n = 26; *AagTg* NDMA = 18. See also Figures S2 and S4. Bar graphs show the median with data points representing individual animals. Mann-Whitney *U*-test, ***p* < 0.01, ****p* < 0.001, #*p* < 0.0001.




Figure 2. AAG levels modulate NDMA-induced phosphorylation of H2AX and micronuclei. A) Staining of γ H2AX in NDMA-treated livers can appear as punctate foci (white arrow), pan-nuclear (red arrows) or super-bright pan-nuclear (red asterisk). Scale bar = 10 μ m. B) Example of a hepatocyte with two micronuclei (yellow arrows). Image adapted from (Avlasevich et al., 2018) with permission from the authors and publisher. C) NDMA exposure increases the number of cells harboring an increase in punctate γ H2AX foci 24h post-exposure. Nuclei containing 5 or more foci were counted as γ H2AX-positive. D) NDMA increases the frequency of cells with pan-nuclear γ H2AX signal 24h post-

exposure. E) NDMA increases the frequency of super-bright pan-nuclear γ H2AX stained cells 24h post-exposure. F) NDMA induces micronucleus formation in hepatocytes 48h post-exposure. See also Figure S5. Box plots show median with interquartile range, and whiskers show the range. Micronuclei represented as mean \pm SD. For all graphs, each data point represents one mouse (n = 8), and γ H2AX data points are averaged from two independent regions of one slide. Unpaired Student's *t*-test; **p* < 0.05, ***p* < 0.01, ****p* < 0.001, #*p* < 0.0001.




Figure 3. Imbalanced BER exacerbates NDMA-induced cytotoxic liver damage 24h post-exposure.

A) Quantitative analysis of cleaved caspase-3-positive apoptotic hepatocytes. Histopathological analysis indicates elevated B) centrilobular hepatocellular necrosis, C) hepatocellular degeneration, and D) inflammatory cell infiltration in all genotypes. Bars indicate the median of scores from individual mice (n = 8). Caspase scores were calculated from the sum of 4 independent regions of one slide. Mann-Whitney *U*-test, **p* < 0.05, ***p* < 0.01, ****p* < 0.001. See also Figure S6.




Figure 4. *Aag*^{-/-} mice have increased susceptibility to NDMA-induced cancer and *AagTg* mice are resistant.

Mice unable to excise the 3MeA lesion (*Aag*^{-/-}) are more prone to developing tumors in greater numbers than WT and *AagTg* mice. Lines indicate the median, and each data point represents an individual mouse (n = 24 for each group except *Aag*^{-/-}, where n = 22). Mann-Whitney *U*-test, ****p* < 0.001, #*p* < 0.0001.




Figure 5. Integration of phenotypic endpoints over time shows that reduced toxicity and increased mutations lie upstream of cancer in *Aag*^{-/-} mice, and DNA damage and cytotoxicity precede lethality in *AagTg* mice.

Radar plots showing key endpoints from this study in chronological order. Medians or means from each group for each endpoint are normalized to the highest scoring group at that endpoint (*e.g.*, NDMA-treated *Aag*^{-/-} mice have the highest tumor burden, so medians of all groups were normalized to the median *Aag*^{-/-}). Similarly, NDMA-treated *AagTg* mice

showed the highest micronucleus induction, so means of MN results were normalized to the *AagTg* mean.)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1.

AagTg mice suffer acute lethality from NDMA exposure.

	Total animals injected w/NDMA	Total dead within two weeks	Premature lethality (% injected)
WT	137	1	0.7
<i>Aag^{-/-}</i>	93	1	1.1
<i>AagTg</i>	102	13	12.7

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2.

AAG activity modulates liver cancer susceptibility.

	Median # tumors/mouse	Incidence (% mice with tumors)
WT	1	16/24 (67%)
<i>Aag^{-/-}</i>	4.5	19/22 (86%)
<i>AagTg</i>	0	10/24 (42%)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Rabbit monoclonal anti-phospho-Histone H2A.X (Ser139)	Cell Signaling Technology	Cat# 9718; RRID: AB_2118009
Rabbit polyclonal anti-Ki67	Abcam	Cat# ab15580; RRID: AB_443209
Rabbit monoclonal Cleaved Caspase 3 (Asp175)	Cell Signaling Technology	Cat# 9664; RRID: AB_2070042
PTMScan Phospho-ATM/ATR Substrate Motif (pSQ) Kit	Cell Signaling Technology	Cat# 12267
Bacterial and Virus Strains		
E. coli YG6020	Nohmi et al. 1996	N/A
Biological Samples		
Chemicals, Peptides, and Recombinant Proteins		
N-nitrosodimethylamine	This paper	CAS: 62-75-9
Sequencing grade Trypsin	Promega	Cat# V5111
5 μm C18 beads, ODS-AQ	YMC	AQ12S05
TMT10plex reagent	Thermo Scientific	Cat# 90406
Critical Commercial Assays		
Prototype In Vivo MicroFlow® BASIC ML Kit	Litron Laboratories	N/A
Prototype In Vivo MicroFlow® PLUS ML Kit	Litron Laboratories	N/A
RecoverEase DNA Isolation Kit	Agilent Technologies	Cat# 72023
High-Select Fe-NTA Phosphopeptide Enrichment Kit	Thermo Scientific	Cat# A32992
Deposited Data		
Mass spectrometry proteomics data	This paper	ProteomeXchange Consortium PXD021142
Experimental Models: Cell Lines		
Experimental Models: Organisms/Strains		
Mouse: B6.129S4(Cg)- <i>Gt(ROSA)26Sor^{tm1(CAG-EGFP*)Bpenq}/J;gp^{fl/e}</i>	This paper	N/A
Mouse: B6.129S4(Cg)- <i>Gt(ROSA)26Sor^{tm1(CAG-EGFP*)Bpenq}/J;gp^{fl/e};Aag^{-/-}</i>	This paper	N/A
Mouse: B6.129S4(Cg)- <i>Gt(ROSA)26Sor^{tm1(CAG-EGFP*)Bpenq}/J;gp^{fl/e};Aag^{Tg}</i>	This paper	N/A
Oligonucleotides		
Recombinant DNA		
Software and Algorithms		
Proteome Discoverer 2.2	ThermoFisher	https://www.thermofisher.com/us/en/home/industrial/mass-spectrometry/liquid-chromatography-mass-spectrometry-lc-ms/lc-ms-software/multi-omics-data-analysis/teome-discoverer-software.html
Mascot version 2.4	Matrix Science	http://www.matrixscience.com/
Prism 8	GraphPad Software, LLC	https://www.graphpad.com/scientific-software/prism/
ImageJ	National Institutes of Health	https://imagej.nih.gov/ij/

REAGENT or RESOURCE	SOURCE	IDENTIFIER
KNIME 4.0.1	KNIME AG, Zurich, Switzerland	https://www.knime.com/downloads
Ilastik 1.3.2	Berg et al., 2019	https://www.ilastik.org/
QuPath 0.2.1	Bankhead et al., 2017	https://qupath.github.io/
Matlab R2016a	MathWorks	https://www.mathworks.com/products/new_products/release2016a.html
Python 3.6.0	Python	https://www.python.org/downloads/release/python-360/
FACSDiva™ v6.1.3	BD Biosciences	https://www.bdbiosciences.com/ca/instruments/clinical/software/flow-cytometry-acquisition/bd-facsdiva-software/bd-facsdiva-software-v-613/p/643629
RaDR foci counting algorithm	This paper	https://github.com/dushanw/RPN_RCN_roiExtractor
Other		

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript